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Varicella Zoster Virus is the causative agent of varicella (chickenpox) upon primary infection 
and zoster (shingles) upon reactivation from latency. Viral reactivation causes neurological 
complications, with pain being the most common. Almost all zoster patients are prescribed 
medication to alleviate pain and up to one third will develop a chronic pain state that lasts longer 
than 30-90 days known as Post-Herpetic Neuralgia (PHN). A majority of these PHN patients 
describe pain in one of three ways: a constant burning, intermittent stabbing or shooting, and 
lastly allodynia (pain from normally innocuous stimuli), which is the most common and 
debilitating. A rat model of VZV-induced pain was established in 1999 which mimics the pain 
seen in humans. The goal of this thesis is to utilize the rat model of VZV-induced pain to 
characterize the viral effects on the host, investigate mechanisms that result in chronic 
hypersensitivity, and to evaluate novel treatment strategies. We have discovered that viral 
infection of rat tissue ex vivo is limited, viral DNA persists at low levels early in infection, and 
viral RNA transcription is limited to immediate early and early expressed genes. We investigated 
host changes upon VZV infection which include a decrease in peripheral neurite innervation 
density and changes in whole dorsal root ganglia transciption with up-regulation of 86 genes and 
down-regulation of 114 host genes. We show that ORF47, a viral protein kinase, is both 
necessary and sufficient for the induction of hypersensitivity in rats, and this effect may be 
related to its phosphorylation of ORF9, an essential tegument associated protein. Interestingly, 
ORF47 may not be the only VZV protein involved in the induction of hypersensitivity, as 
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animals transduced with an HSV vector expressing IE62 also develop hypersensitivity to 
mechanical stimuli, suggesting a role for IE62 in VZV-induced pain. Lastly, we tested novel 
herpes simplex vectors that express pain relieving genes for their efficacy on VZV-induced pain. 
Vectors delivering human preproenkephalin, an endogenous opioid peptide, and soluble TNFα 
receptor alleviate hypersensitivity in our model. The rat model has enabled us to better 
understand and treat VZV-induced pain. 
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1.0  INTRODUCTION 
Varicella zoster virus (VZV), an alphaherpesvirus, is a ubiquitous human pathogen that causes 
severe neurological complications upon its reactivation from a state of neuronal latency. Pain is 
the most commonly described complication from VZV reactivation. A subset of patients 
experience a chronic neuropathic pain state known as postherpetic neuralgia (PHN). PHN is 
often debilitating and can last for years after the rash resolves. Current treatments leave many of 
these chronic pain patients without adequate relief and often with unwanted side effects. The 
goal of this thesis project was to use a rat model of VZV-induced pain to investigate the 
underlying viral and host mechanisms contributing to pain and to evaluate novel treatment 
strategies. 
1.1 CLINICAL CHARACTERISTICS AND DISEASE 
1.1.1 Primary Infection and Clinical Presentation 
Varicella zoster virus (VZV) causes two human diseases; varicella upon initial infection and 
herpes zoster upon viral reactivation from latency established in neurons of sensory and 
autonomic ganglia. Most varicella cases are reported in childhood, but may also occur in adults 
with often devastating consequences 1. Varicella is almost always associated with a red, 
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vesicular, pruritic rash that covers most of the body. Prodromal symptoms associated with 
varicella include fever, malaise, headache, and abdominal pain. The incubation period between 
initial infection and eruption of a rash can last 10 to 21days 1. VZV is spread predominantly by 
aerosolized viral particles that are inhaled, but contact with infectious fluids and rash can also 
spread the virus 1,2. Once inhaled, viral particles infect upper respiratory tract epithelial cells 
around the Waldeyer’s ring, which include the adenoids and tonsils. The virus then infects 
immune cells including various antigen-presenting cells such as dendritic cells that can traffic to 
lymphoid organs and transmit the infection to other immune cells 3-6. Infection of immune cells, 
particularly T cells, enables a blood-based viremia that allows for the efficient transfer of the 
virus to the skin 7. At the skin, the virus replicates in the dermis and then epidermis where it 
generates the characteristic rash. At the skin viral replication leads to lesions that form for 3 - 6 
days and eventually heal and scab over. VZV infects and establishes latency in neurons of the 
sensory and autonomic ganglia, which occurs in one of two ways: infection of axons innervating 
the skin allow the virus to infect neurons via retrograde transport; or by VZV infected circulating 
T cells that infiltrate into ganglia and infect ganglionic cells. The T cell based viremia likely 
accounts for VZV establishing a latent state in all sensory and autonomic ganglia along the entire 
peripheral neuraxis, as VZV nucleic acids are found in virtually every ganglia 8,9.  
Contracting varicella in adulthood has serious implications. Fatalities, while rare, are 
increased in adults and children over the age of 4 10. Complications associated with varicella 
include secondary bacterial infection, varicella pneumonia, and neurological symptoms. 
Contracting varicella during pregnancy, especially the first trimester, can be serious as VZV is 
one of the few pathogens that can be passed between mother and child while in the womb 
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causing birth defects. Vaccination and treatment with antiviral medication and antibodies reduce 
this risk 11. 
VZV is a ubiquitous human pathogen that affects humans worldwide. Cases of varicella 
were as high as 4 million a year in the United States when vaccination was not required. 
However, epidemic varicella has largely been eradicated in this country and others that require 
vaccination, which has resulted in 82% fewer varicella cases between 2000 and 2010 12. In the 
United States and other temperate countries, 99.6% of adults between the ages of 40 and 49 have 
antibodies directed at VZV suggesting prior VZV infection or vaccination 13. However, adults in 
tropical regions are far more susceptible to infection with as low as 50% of adults seropositive 
for VZV antibodies 14. 
The requirement for vaccination against varicella in the US and other countries has 
largely reduced epidemic spread of varicella and the associated morbidity and mortality. 
However the majority of countries do not require vaccination and therefore have endemic VZV, 
which can flare up as varicella epidemics. With increased vaccination, an increasingly aging 
population, and without the natural boost in immunity derived from epidemic VZV, zoster 
incidence is rising. VZV remains a public health concern that is largely unmet and in need of 
new treatments. 
1.1.2 VZV Latency and subclinical disease 
After primary infection, viral genomes remain latent with few apparent reactivation events over 
the lifetime of the host. VZV remains latent for the life of the host in neurons of the peripheral 
nervous system. Valuable information has been gained through the examination of post mortem 
tissue from VZV infected individuals. The burden of viral genomes in latently infected human 
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sensory ganglia varies widely with estimates of between 258±38 and 9,046±13,225 viral copies 
per 100,000 ganglionic cells in two studies 15,16. These numbers vary greatly due to small sample 
size n=18 and 17 respectively, and variations in the burden of infection between individuals in an 
outbred human population 17. Latent viral genomes exist as a circularized episome separate from 
the host genome that becomes associated with heterochromatin 17-19. This heterochromatinated 
state likely reduces viral gene expression to a select few genes that may be less chromatinated. 
Viral gene expression during latency has been controversial with early reports detecting viral 
transcripts (ORF21, 29, 62, 63, and 66) with ORF63 transcripts and protein expression proposed 
to be the hallmark of latency 20-22. These findings have recently become contentious as viral gene 
transcription is now recognized to increase with post mortem interval 23 and ORF63 and other 
viral protein expression has also been called into question with the recent revelation that many of 
the antibodies used in these studies cross-react with blood group A antigens 24,25.  
There are several animal models of viral latency that recapitulate some of the hallmarks 
of viral latency in humans, but there are no models in which this latency can undergo 
reactivation. Rats, SCID-hu mice, guinea pigs and non-human primates have all been used as 
models of latency. These models have suggested a reduced number of viral transcripts with a 
proposed hallmark IE63 expression in innervating ganglia, although this may be questionable. 
Non-human primates have been used to model VZV infection and latency, using a close relative 
of VZV, simian varicella virus, which has many similarities to VZV, but has differences and has 
evolved with non-human primates. The requirements of VZV genes for latency has also been an 
important question investigated in cotton rats with 16 VZV gene deletion mutants tested for their 
ability to establish and maintain latency in cotton rats. Mutant viruses that lack the expression of 
ORFs 4, 29 and IE63 show impairment in the establishment of latency 26. This data is 
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contentious as the cotton rat model does not have detectable reactivation and may represent an 
abortive infection rather then true latency. 
1.1.3 Reactivation and its subsequent disease 
Viral reactivation from latency results in a disease known as herpes zoster. An estimated 
32% of people will have herpes zoster during their lifetime, with the main risk factor being age 
27. Other risk factors for zoster, besides age, include: cancer, as zoster is frequently reported 
among patients with leukemia, Hodgkin's and non-Hodgkin's lymphoma, and small cell 
carcinoma of the lung 1,28; transplantation and the associated immune suppression, HIV, and 
more recently stress from zero gravity 1,27,29. The incidence of zoster has also been documented 
to be lower in blacks than whites 27. Most of these risk factors involve decrease in immune 
function and therefore it is likely that the immune system plays a large role in containing VZV 
reaction. Herpes-zoster is characterized by a vesicular rash with surrounding erythema that 
encompasses 1 or 2 dermatomes and is often accompanied by pain and other neurological 
symptoms 30. The molecular events governing VZV reactivation are not well understood but are 
thought to follow, the closely related alphaherpes virus, HSV1. Viral reactivation is likely the 
result of a general derepression of chromatinated viral DNA, followed by expression of viral 
proteins and may or may not result in virus production. Zoster patients that have recently 
reactivated have been intranuclear inclusions, viral antigens, and virus particles in sensory 
ganglia 31,32. The large rash is a result of intraganglionic spread between neurons and 
surrounding cells during reactivation which results in the delivery of virions, en masse, to the 
periphery where viral infection of epithelial cells occurs with an associated inflammation 33-35. 
VZV reactivation is associated with pathological features that include: ganglionic inflammation 
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and hemorrhagic necrosis with neuritis, possible localized meningitis, degeneration of related 
motor and sensory roots, necrosis or apoptosis of infected neurons, and demyelination likely 
resulting from mononuclear cell infiltration of microglial activation 36,37.  Together this damage 
to neurons caused by reactivated VZV has effects on neurological functions and usually results 
in, at least, pain. 
During reactivation virions are not only delivered to the periphery but also to the central 
nervous system where they can cause severe but rare complications including myelitis, aseptic 
meningitis, encephalitis, and even vasculopathies leading to stroke 38. Viral reactivation causes 
neurological complications that can become chronic including: itch, paresthesia, loss of 
sensation, and most commonly pain 34. Herpes-zoster can be predicted by prodromal signs 
include: paresthesia, numbness, itch, and importantly pain (preherpetic neuralgia), which can 
precede the eruption of the rash by as much as 100 days 39. Zoster associated pain can occur 
before, during or after resolution of the vesicular rash and is an extremely common result, with 
up to 90% of unvaccinated patients prescribed medication to alleviate pain 30,40. The prevalence 
of zoster patients that develop chronic pain long after the rash has resolved is estimated to be 
between 10 to 30%, with incidence increasing with age 41,42. This subset of zoster patients 
experience a chronic neuropathic pain state known as postherpetic neuralgia (PHN), which is 
defined as pain lasting longer than 30-90 days after resolution of the herpes zoster rash.  
Models for viral reactivation have been largely nonexistent, as the virus has proved to be 
difficult to reactivate. Prolonged culturing of excised latently infected human ganglia does not 
result in viral reactivation and there is no release of detectable infectious viral particles. There 
are two reports of experimental reactivation in guinea pig and rat latently infected excised 
  6 
neurons, but both have yet to be validated in other laboratories 26,43,44. Overall, there is still much 
to discover about VZV reactivation that has been hampered by the lack of a small animal model. 
1.1.4 Vaccines 
In the US there are two commercially available vaccines, one for the prevention of 
varicella (Varivax) and one for the prevention of herpes zoster (Zostavax). Both vaccines utilize 
live-attenuated strain(s) developed in Japan after serial passage in guinea pig cells, followed by 
passage in human cells 45-47. Both vaccines are well tolerated with limited adverse events and few 
breakthrough VZV infections and both vaccines generate broad humoral and cellular immunity 
48-51. Varivax is up to 85% effective at reducing varicella and has largely eradicated VZV 
epidemics in the countries that require vaccination 52. However, breakthrough varicella and has 
been reported, although vaccinees have reduced burden of primary disease and adverse effects 53. 
As the Varivax is an attenuated virus, the vaccine virus can still establish latency, reactivate, and 
cause neurological disease but at reduced incidence compared to wild type VZV. 
The herpes-zoster vaccine (Zostavax) has an increased dose, 14 fold higher, compared to 
the varicella vaccine. Zostavax is much less effective, with only a 51% reduction in the incidence 
of herpes-zoster and 66.5% reduction in burden of illness including postherpetic neuralgia 54. 
Only 27% of patients older than 60 years of age are vaccinated, largely from unwillingness of the 
target population to receive the vaccine, lack of knowledge of the disease, and medical 
professionals not recommending the vaccine 55,56. This leaves a substantial portion of vaccinated 
patients that can experience vaccine or wild-type VZV reactivation and the associated pain. This 
will no doubt become an increasing public health concern as our population ages and lives 
longer. 
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1.2 VZV BIOLOGY 
Our knowledge of initial infection by varicella-zoster virus has greatly improved with the 
development of new in vitro and in vivo models. However our knowledge of viral latency and 
reactivation are still inadequate and require new models to further our understanding of these 
phenomena. The study of VZV is hampered by a number of complications of working with the 
virus. First, VZV is highly human specific and does not readily infect non-human cells or 
animals, unless adapted for growth in those cells. Secondly, in vitro generated VZV is highly cell 
associated and yields very low levels of cell free virus, which affects our ability to achieve 
synchronous infections therefore limiting our knowledge of the kinetics of viral expression. 
Lastly, viral reactivation from latency has been hard to experimentally reproduce. With these 
drawbacks, much of what we hypothesize about VZV is assumed from a certain degree of 
homology between VZV and the more easily studied Herpes Simplex Virus (HSV). 
1.2.1 Classification and genome. 
Varicella Zoster virus (VZV) belongs to the herpesvirinae family, subclassified as an 
alphaherpesvirus. VZV is a double stranded DNA virus with a 125-kilobase genome, which can 
be separated into unique long and unique short sections both flanked by repeat regions (Figure 
1). Unique short flanking repeats of VZV are large, but unique long repeats much smaller, only 
88.5bp 1. The genome is packaged in two predominant isomers with a fixed UL orientation and 
two different orientations of the US region, dictated by packaging sequences in the left-hand end 
of the UL region 57.  
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 Figure 1: Schematic of HSV and VZV genomes. The HSV1 genome is about 148 kilobases where as the 
VZV genome is only about 125 kilobases. Both alphaherpesviruses have repeat regions that flank unique regions. 
The genomes to be represented as: terminal repeat long (TRL), unique long (UL), internal repeat long (IRL), internal 
repeat short (IRS), unique long (US), and terminal repeat short (TRS). VZV has smaller unique long flanking repeats 
(as small as 83.5 base pairs) than HSV. 
VZV is closely related to Herpes Simplex Virus (HSV) with much of VZV biology based 
on its similarity to HSV. Overall the gene order and direction of orthologous VZV and HSV 
genes is the same, such that they are colinear and positionally the same. VZV encodes 70 open 
reading frames with all but six (ORFs 1,2,13,32,57 and S/L) having orthologs in HSV. VZV 
encodes its own DNA polymerase (comprised of ORFs 28 and 16), which is sensitive to 
acyclovir once the drug is processed by the viral thymidine kinase (ORF36). VZV also encodes a 
ribonucleotide reductase (comprised of ORFs 18 and 19) that converts ribonucleotides to 
deoxyribonucleotides. At least 2 DNA binding proteins ORF29, which binds single stranded 
DNA, and ORF51, which binds to the viral origin of replication, are encoded by VZV. The virus 
has two protein kinases, ORF47 and 66, which will be discussed in further detail in chapter 3. 
VZV has seven glycoproteins: gB, gC, gE, gH, gI, gK, gL, gM and gN 1.  
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1.2.2 Viral Particle and in vitro Lifecycle 
 The virion itself is made up of a capsid that surrounds one copy of the genome; a proteinacious 
tegument and an envelope studded with viral glycoproteins. The mature, infectious enveloped 
VZV particle is pleomorphic to spherical in shape and up to 200-400 nm in diameter. The capsid 
is made up of 162 capsomeres in a 5:3:2 axial symmetry. The viral proteins that make up the 
capsid have not been defined but are presumed to be the VZV homologs of the genes that make 
up the HSV capsid. The tegument surrounding the capsid allows the virion to transport proteins 
that help establish viral infection and these include ORFs 4, 10, 47, 62, 63, and 66. The capsid is 
assembled in the nucleus and is transitionally enveloped as it exits from the nucleus at the 
nuclear membrane. The initially budded viral particles can de-envelop into the cytoplasm and 
undergo secondary envelopment at the Golgi. Particles can also capture membrane from the 
rough endoplasmic reticulum (ER), cytoplasmic vesicles, and the cell surface 1. Our 
understanding of viral egress is far from complete and would likely be better understood once 
synchronized infections with cell-free virus are achieved.  
Initial virion attachment is mediated by cell type specific receptors including insulin 
degrading enzyme and mannose-6-phosphate 58-60. After initial attachment the virion enters the 
cell by fusion of the viral envelope with the cytoplasmic membrane or is taken up by 
endocytosis. Once the cell is infected, viral tegument associated proteins are hypothesized to be 
transported with the uncoated capsid to the nucleus, where they likely promote efficient viral 
gene transcription and productive infection. Immediate early messenger RNAs (mRNAs) are 
transcribed in the nucleus, transported to the cytoplasm, translated, and the proteins they encode 
are brought back to the nucleus. Immediate early proteins allow for the efficient transcription of 
early mRNAs that are again transcribed in the nucleus, translated in the cytoplasm, and some are 
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transported back to the nucleus, where they facilitate viral DNA replication. After viral DNA 
replication has started late genes are transcribed and translated, with some of the proteins 
transported back to the nucleus while others become associated with the host membranes, 
cytoplasm and cytoplasmic structures. Capsids form in the nucleus, which have viral DNA 
loaded into them through a portal structure. These completed and filled capsids are transported 
out of the nucleus through an envelopment/de-envelopment process at the nuclear membrane. 
The viral tegument, which is made up of ORFs 4, 10, 47, 62, 63 and 66 61-63, and viral 
glycoproteins are acquired as the virion becomes re-enveloped at the transgolgi network. Some 
of these virions will reach the plasma membrane and bud off, but others will be diverted to 
lysosomes and are degraded 60,64. This lifecycle results in the release of infectious virions 
between 8-16 hours post infection with viral proteins detected as early as 4 to 6 hours after 
infection 1. 
In VZV and HSV, viral gene expression is carefully regulated during infection and 
separated into three categories (Figure 2). Genes transcribed without other viral gene expression 
or in the presence of translation blocking drugs such as cyclohexamide, are known as immediate 
early genes; genes expressed after immediate early genes but before viral DNA synthesis (or in 
the presence of a viral DNA synthesis inhibitor such as phosphonoacetic acid), are termed early 
genes; and those genes that are expressed maximally after viral DNA replication, are defined as 
late genes. In general immediate early genes are responsible for turning on early genes, which in 
turn are responsible for replicating viral DNA, which once started allows late genes to be 
expressed; which encode structural proteins that include those involved in capsid formation and 
DNA packaging. VZV gene expression is thought to largely follow the pattern defined for HSV, 
  11 
but has not been experimentally determined because synchronous infection with VZV is 
currently not possible. 
 
Figure 2: Schematic of the temporal cascade of viral gene expression in human alphaherpes viruses. 
The temporal expression cascade of viral genes is highly regulated and separated into immediate early, early, and 
late gene expression patterns. This expression pattern allows for the detection of a possible block in replication in 
non-permissive cells. 
VZV has four putative immediate early genes based on their homology to HSV IE genes: 
IE62, IE61, IE63, and IE4 all of which have been shown to affect viral transcription events.  
Of the immediate early genes, IE62 is arguably one of the most important and is required 
for viral replication in vitro and in vivo 65. The protein is found in the tegument of virions and in 
the nucleus of infected cells, however phosphorylation of IE62 by the two viral protein kinases, 
ORFs 47 and 66, affects its subcellular localization 63,66,67. IE62 is the homolog of ICP4 in HSV1 
and can inefficiently complement an ICP4 deficient mutant virus 68. It is the major viral 
transactivator, responsible for promoting gene transcription of early and late genes. In transient 
expression assays, IE62 activates expression of all three temporal gene classes 69,70. IE62 is used 
to boost expression of viral genes in vitro and to increase the infectivity of viral DNA. IE62 
activates diverse promoters by interacting with various cellular transcription factors including 
SP1, TATA-binding proteins, TATA-binding protein complexes, and the mediator complex 71-73. 
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IE63 encodes a tegument-associated phosphoprotein. IE63 has homology to HSV1 US1.5 
protein, which is collinear with HSV ICP22 74. Work from one group suggests IE63 is required 
for infectivity, while another group reports IE63 deficient viruses can replicate, albeit 
inefficiently 75,76.  IE63 has been suggested to be essential for the establishment of latency in 
cotton rats 74,75. Transcription and protein expression of IE63 in latently infected ganglia has long 
been used as a hallmark for viral latency in humans, but as reported earlier, this has come into 
question 77. During infection, IE63 primarily localizes to the nucleus but at early time points it is 
found in the nucleus 78. Cellular kinases, Casein kinases I and II, and Cyclin dependent kinase 1 
and 5 can phosphorylate the C terminus of IE63 78,79. Phosphorylation of IE63 is necessary for 
viral growth in skin, but not T cells in the SCIDhu model 74. 
Another immediate early gene associated with the tegument is IE4. IE4 is the ortholog to 
HSV ICP27, but does not complement an ICP27 deficient mutant virus 80. IE4 can transactivate 
immediate early, early, and late viral genes but does not share the transrepressor activity of 
ICP27 81-83. IE4 has been shown to interact with many proteins involved in transcription 
including: TFIIB (the TATA binding protein), two subunits of NF-κB; p50 and p65, and IE4 also 
binds to IE62 84,85. IE4 may have posttranscriptional regulatory activities 86. Deletion of IE4 
impairs viral latency in cotton rats, with fewer latently infected animals and lower viral burden in 
those animals.   
The putative immediate early gene is IE61 encodes a phospho-protein that localizes to the 
nucleus during infection 87,88. Unlike the other immediate early genes, IE61 is not associated with 
the tegument and is therefore not brought in with the virus particle during infection 62. IE61 can 
either activate or repress IE4 and IE62 in plasmid transfection studies depending on cell type and 
transfection conditions 70,89,90. IE61 is the ortholog to HSV1 ICP0 and can complement an ICP0 
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deletion virus suggesting they exhibit similar function91. IE61 is not necessary for viral growth in 
culture, but does effect syncytia formation, and deletion of IE61 does not effect establishment of 
viral latency 92,93. Recently a role for IE61 in counteracting an intrinsic antiviral defense has been 
uncovered in which, promyelocytic leukemia protein (PML) cages that envelope incoming viral 
DNA is partially counteracted by ORF61 protein 94,95. Like HSV1 ICP0, ORF61 possesses a 
RING finger domain, and localizes to nuclear domain 10 bodies to affect their structure. 
However, while some intrinsic cellular defenses are degraded by both ICP0 and ORF61, the 
latter does not degrade PML. 
This virus encodes two early expressed, serine/threonine kinases, ORF47 and ORF66. 
Both virally encoded protein kinases are dispensable for viral growth in vitro, but both are 
known to be necessary for different stages of in vivo spread. The ORF47 kinase is acidophilic 
with a consensus phosphorylation motif similar to human casein kinase II. A deduced motif of: 
S/T-X-D/E-D/E has been identified with a preference for acidic amino acids -1 or +1 173. The 
kinase appears to have orthologs in all herpesviruses, and is similar to the UL13 kinase of HSV1 
The targets for ORF47 have not been fully elucidated, but it is known to phosphorylate several 
viral proteins including: itself, IE62 (the major transactivators of viral gene expression), ORF9 (a 
tegument protein), and ORF32 131,174,175. The only known host target is IRF3, but it seems likely 
there are others176.  
The second viral kinase, encoded by ORF66, is a serine/threonine kinase that is the VZV 
ortholog to HSV1 and PRV US3, a kinase that is conserved among the alphaherpesviruses. 
ORF66 is a basophilic kinase with a target serine preceded by lysines and/or arginines 177. 
ORF66 has several known targets including itself, IE62, Matrin 3, and HDAC 1 and 2 128,178-180. 
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The target motif of ORF66 overlaps with protein kinase A. Viruses deficient in ORF66 exhibit 
reduced growth in T cells and corneal fibroblasts in vitro 128,181.  
Both kinases are necessary for growth in certain cells in vivo. ORF47 is necessary for 
productive viral growth in T cells and skin in the SCID-hu model and an ex vivo model of human 
T cell VZV infection, as well as for transferring infection from dendritic cells to susceptible 
fibroblasts 158,181,182. Loss of ORF47 kinase function results in aberrant capsid formation that 
results in decreased cell free spread in vivo 67,182,183. ORF66 is needed for efficient viral 
replication in T cells in a SCID-hu model but has only a slight reduction in growth in skin 184,185. 
Therefore, while both kinases are dispensable for viral growth in vitro, but clearly affect 
virulence in vivo. 
ORF9 is a late expressed, tegument-associated gene that is essential for viral growth 
186,187. During infection, transcripts from the ORF9 gene are readily detected and when 
quantified, are the most abundant viral transcripts 188,189. ORF9 is the ortholog of HSV1 UL49 
and shares homology with the UL49 encoded protein, VP22 of HSV1. ORF9 interacts 
extensively with viral proteins including IE62, gE, gI, gH, gN, ORF15, ORF23, ORF38, and 
ORF47 186,190-193. These extensive interactions likely make ORF9 important in proper tegument 
and virion formation, as ORF9 hyperphosphorylation (mediated by ORF47 at Serine 84) 
influences virion formation and egress 193. 
 
1.2.3 Animal models of varicella zoster virus latency 
Small animal models of VZV infection and latency are largely hindered by the inability of VZV 
to replicate in most non-human tissues. Viral latency has been reported in several small animals 
  15 
including laboratory rats, cotton rats, and guinea pigs, but these models have been criticized, as 
they do not support viral growth. Other groups have modeled VZV infection using explanted 
human fetal tissue into SCID mice. While this has enabled the study of factors affecting initial 
viral infection and the innate immune system’s role in controlling VZV infection they lack neural 
connectivity and an adaptive immune system. There are no reproducible models of viral 
reactivation in animals, with the possible exception of two reports 26,43,44,96. The models include: 
1.2.3.1 Guinea Pigs 
The vaccine was passaged in guinea pig cells, which provide some permissivity to VZV growth. 
These animals have also served as a model for varicella zoster virus infection and latency. 
Animals inoculated with a guinea pig adapted virus can transmit the virus between animals and 
exhibit some of the hallmarks of human infection including a monocyte associated viremia 97,98. 
Animals may develop a rash in rare cases. VZV proteins and nucleic acids have been detected in 
sensory as well as enteric ganglia in animals, and the virus can become latent 44,99. Recently this 
model has been expanded to investigate the effects of VZV infection on enteric neurons. 
Interestingly, when dissociated enteric neurons are exposed to cell-free VZV (that was not 
adapted for growth in guinea pigs) the virus infects neurons and expresses viral genes, but does 
not cause cytopathic effect until superinfected with Adenovirus vectors expressing ORF61 or its 
HSV homolog ICP0, at which time cytopathic effect and viral reactivation were reported 44.  As 
these animals are fully immunocompetent, this model enables the study of immune responses to 
VZV with infected animals seroconverting and exhibiting a T cell response to infection 100-102. 
The major disadvantage of this model is its need for adapted virus, which may have 
characteristics and mutations that make extrapolation of the data to human disease more difficult.  
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1.2.3.2 SCID-hu Mice 
The lack of wild type VZV replication in virtually all small animal models led to the 
development of the SCID-hu model for VZV. Severely compromised immune deficient mice are 
implanted with human fetal DRG, skin, or thymus/liver tissues, which are accepted, as there is 
no adaptive immune system and cannot be rejected by the host. This model has revolutionized 
some of our understanding of primary VZV infection and has led to interesting data regarding 
viral persistence. Cell associated VZV injected into DRG xenografts results in immediate 
changes to the tissue, including denucleation of neuronal cell bodies, cytoplasmic inclusions, and 
production of quantifiable infectious progeny virus 103. During initial infection, IE63 
immunoreactivity is readily detected in neuronal and satellite cells. VZV infection also results in 
polykaryon formation between neurons and support cells that have assembled capsids, but 
produces no appreciable changes to cellular organelles. These changes suggest full viral 
replication without the accompanying cell death 104. By 8 weeks post infection the acute viral 
lifecycle changes into a state of persistence or latency within the DRG in which only IE63 RNA 
is detected but at low levels 105,106. Few IE62, 63 and ORF31 transcripts are detected during this 
stage and no viral proteins are detected during persistence, as seen for recent data in humans 
105,107. Interestingly SCID-hu DRG mice infected with the live attenuated vaccine strain have 
similar numbers of persisting/latent genomes and similar replication in neural tissue as wild-type 
virus 103. These data confirm the ability of the vaccine to enter latency, as seen in vaccinated 
patients that have zoster at the site of vaccination. 
This model added another potential route of viral infection of ganglia in which infected T 
cells, injected into the tail vein of mice, traffic to and infect implanted neural tissue 106. This 
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finding has changed the way we think about how VZV reaches the ganglia and may explain how 
VZV can reach ganglia along the entire neuraxis.  
While we have learned a great deal about VZV pathogenesis from this model, it is not 
without its drawbacks. Mice are not a natural host for VZV and therefore this model is highly 
artificial. Secondly, these animals have no adaptive immune system and therefore the study of 
the immune responses to VZV is out of the question and may change the way the host interacts 
with the pathogen. Lastly, the model relies upon fetal tissue that may be hard to acquire and may 
not behave like more mature, post natal ganglionic tissue. 
1.2.3.3 VZV Latency in Rats and other rodents 
VZV infection of dissociated rat neurons led the same research group to inoculate laboratory rats 
with VZV injections along the spine 108. Viral proteins and nucleic acids were detected in 
nervous tissue at 6 and 9 months post infection, respectively 43. Interestingly, an initial report 
suggested that viral nucleic acids are present in both neurons and non-neuronal cell types in 
ipsilateral DRGs when the dorsal root was severed prior to VZV inoculation along the spinal 
cord. This may suggest limited hematogenous spread of the virus 109.  
Other groups have inoculated rats at the footpad and skin with VZV nucleic acids 
detected in innervating ganglia by in situ hybridization. VZV DNA was detected in both 
ipsilateral and contralateral ganglia in both non-neuronal and neuronal cell types 20,110. Viral 
DNA and RNA have been reported to persist in rats for up to 18 months post infection possibly 
indicating viral latency in these animals. While genomes persist, there is no evidence that it is 
infectious or capable of reactivation. We argue viral infection of rat tissue represents an abortive 
infection. However, rats exhibit chronic hypersensitivity to mechanical and thermal stimuli after 
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VZV infection, to date this is the only small animal model for VZV-induced pain 111. This model 
of VZV-induced pain will be further discussed below. 
Other rodent models that have been reported include newborn rats, corneal injections in 
mice, and a latency model in cotton rats. Newborn rats inoculated with VZV intraperitoneally 
had viral DNA and RNA present to 5-6 weeks post infection 112. Mice infected in the cornea had 
disseminated infection/latency with viral DNA found in the trigeminal ganglia as well as the 
brainstem, kidneys, spleen, and liver at 1 month post infection, although this has never been 
reproduced 113. Viral RNA was also detected in the trigeminal ganglia and spleen 113. Lastly, 
cotton rats infected with VZV establish a latency-like state when injected along the spine 114,115. 
The cotton rat model was used to investigate which viral genes are necessary for “latency”, but 
suffers from the same arguments regarding what the latency state is.  
While these models have allowed us to gain new insights in VZV pathogenesis and 
latency, they leave a lot to be desired. Again the major drawback for all of these models is that 
VZV is a human pathogen that is highly restricted to cells of human origin and infection of 
rodents does not fully recapitulate any of the signs of human disease. Therefore the relevance of 
these models and how they translate to human disease remains to be firmly established. 
1.2.3.4 The VZV-induced pain model in Rats 
There is only one model for VZV-induced pain, in which Wistar or Sprague Dawley rats 
inoculated with VZV at the footpad develop quantifiable chronic hypersensitivity to mechanical 
and thermal stimuli that lasts from 6-14 weeks. This phenomenon was first reported in 1999 and 
has since been expanded upon by several groups including ours 111,116,117. Rats inoculated with 
VZV develop hypersensitivity in the ipsilateral but not contralateral paw, and sham, vehicle, and 
control-cell inoculated animals showing no biased responses on either the ipsilateral or 
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contralateral paws. Severity of hypersensitivity is related to the viral dose in the inoculum, with 
lower doses having a smaller effect on hypersensitivity 118. It has been reported that the same 
animals that have hypersensitivity to stimuli also exhibit anxiety-like behaviors in field paradigm 
tests 117. Importantly, hypersensitivity in the rat is reduced by UV (which I report here) or heat 
inactivation of VZV 116,119 but is not affected by antiviral administration 116,120. These data 
suggest that full, ongoing viral replication is not required to induce hypersensitivity in animals 
but that viral infectivity/ transcription is required.  
Viral gene expression and nucleic acids are detectable in rat nervous tissue out to 6 
months post inoculation in the model, and IE63 and IE62 immunoreactivity have been observed 
in ipsilateral ganglia. IE62 expression appears to colocalize with neuropeptide Y (NPY), 
neurofilament 200 (NF200) and peripherin suggesting peripheral sensory neurons are infected 
with VZV 111,117,118. However, these data have been called into question as the immunoreactivity 
described in these studies do not mimic what is seen in vitro and may be the result of anti VZV 
antibodies exhibiting cross-reactivity with blood group antigens 24. We report that viral DNA and 
RNA are observed in innervating ganglia by quantitative PCR and by others using in situ 
hybridization indicate VZV persists up to 9 months post infection 43,109.  
The host changes in the ganglia induced by VZV infection in rats have not been well 
studied. Animals infected with VZV have increased expression of proteins known to be up 
regulated in some chronic pain states including NPY, galanin, activating transcription factor 3, 
the voltage-gated calcium channel subunit α2δ1, and the sodium channels Nav1.3 and Nav1.8 
when compared to control animals 118. The observed up-regulation of voltage-gated calcium 
channels may partly explain why some pain responds to gabapentin, which blocks these 
channels, as gabapentin is often prescribed to alleviate zoster pain. Another group investigated 
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central mechanisms that may be mediating the chronic hypersensitivity and found increased 
immunoreactivity of GFAP but not OX42 in the spinal cord of VZV infected animals. This has 
been further assessed by intrathecal administration of astrocyte toxin L-α-aminoadipate (LAA), 
which reduced VZV-induced nocifensive behaviors and action potentials, although responses did 
not fully return to baseline. Again, a microglial toxin (minocycline) did not have the same effect 
120. Increases in iNos and IL1β expression were also observed in the spinal dorsal horn of the 
VZV infected animals. They concluded that increased astrocyte activation but not microglia 
might be mediating the chronic hypersensitivity. Taken together, these data suggest there is 
immune activation after VZV inoculation, particularly of astrocytes in the spinal cord, which 
may have a role in VZV-induced pain in this model. 
This model has extensively been used as a platform to test treatments for their effect on 
VZV-induced pain. Compounds that reduced VZV-induced hypersensitivity in the rat model of 
VZV-induced pain are also in use in human patients include morphine, amitriptyline, gabapentin, 
and ibuprofen 117,118. Other novel compounds have been tested in VZV-infected rats that relieve 
hypersensitivity include: a cannabinoid receptor antagonist (Win55212-2 2), sodium channel 
blockers mexiletine and lamotrigine, astrocyte toxin LAA, as well as iNOS inhibitors (L-NIL), 
NO scavengers (PTIO), IL1 receptor antagonist, the cytokine inhibitor pentoxifylline, the 
NMDA receptor antagonists AP5 and (R)-CPP, and the non-competitive NMDA receptor 
antagonist MK801, and lastly histamine H3 receptor antagonists GSK189254 and GSK334429 
117,118,120,121. As this is the only model of VZV-induced pain, it remains the only platform to test 
the efficacy of treatments. 
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1.3 PAIN AND POSTHERPETIC NEURALGIA 
Pain is a complex phenomenon that is defined by the International Association for the Study of 
Pain as “an unpleasant sensory and emotional experience associated with actual or potential 
tissue damage, or described in terms of such damage.” Painful stimuli are sensed in peripheral 
skin tissue by innervating neurons that are classified by their conduction velocities into the fast 
conducting Aβ, slightly slower Aδ, and unmyelinated, slowly conducting C fibers. These fibers 
have various molecular and biochemical characteristics and can be further subdivided based on 
these criteria. However, not every cutaneous innervating neuron responds to painful stimuli, as 
only subsets are able to respond to stimuli in the noxious range. Primary afferents synapse onto 
second order neurons in the spinal dorsal horn where pain signaling is transmitted to higher 
centers in the brain. 
1.3.1 Human Postherpetic Neuralgia and zoster associated pain 
Both chronic and acute zoster associated pain are classified as neuropathic pain. 
Neuropathic pain occurs after an insult to the nervous system, in this case the reactivation of 
VZV from a state of neuronal latency. Zoster associated pain often precedes the characteristic 
rash and can last long after the reactivation resolves. Neuropathic pain can arise from multiple 
etiologies that can be influenced by genetic predispositions and environmental factors making 
treatment of neuropathic pain difficult. Zoster associated pain and postherpetic neuralgia have no 
universal treatment, with a significant portion of PHN patients unable to achieve relief with the 
current armamentarium. 
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1.3.2 Acute Zoster Pain 
Greater than 90% of zoster patients are prescribed medication to mitigate pain 40. This 
pain can be apparent before, during or shortly after onset of the rash 122. Itch, paresthesia, and 
dysesthesia can also accompany VZV reactivation. Most zoster patients experience some 
discomfort and pain, which are thought to be the result of viral replication in the skin and ganglia 
and an associated inflammation. Treatment for acute zoster pain includes antivirals, non-steroidal 
anti-inflammatory drugs, opioids, gabapentin, lidocaine patches and tricyclic antidepressants 123. 
However, in most cases, acute zoster pain resolves with or shortly after resolution of the rash 122. 
1.3.3 Postherpetic Neuralgia 
Pain is the most common complication associated with herpes zoster. Up to 30% of zoster 
patients will develop a chronic pain state classified as postherpetic neuralgia, which can be 
defined as pain lasting longer than 30 days although it may last for months to years. PHN 
patients describe having either spontaneous/on-going pain, stimulus evoked (allodynia) pain, or 
evoked or spontaneous intermittent lancinating pain 124. Acute zoster associated pain is receptive 
to antiviral and corticosteroid treatment, however these treatments have no effect on the chronic 
pain associated with PHN unless administered within 72 of clinical disease 125. PHN can have 
many disparate consequences affecting quality of life, depression, and health care costs 34. PHN 
patients have even gone to extreme lengths to avoid pain including withdrawal from society and 
in extreme cases suicide. Several mechanisms, which are all the result of viral replication and the 
associated damage and cell death, have been proposed to explain the development of PHN 
including irritable nociceptors, deafferented nonallodynic subtype, and deafferented allodynic 
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subtype 126. In patients that have intact peripheral nociceptors, PHN may be a result of abnormal 
nociceptor activity and central sensitization (irritable nociceptor subtype). Patients that have lost 
peripheral C-nociceptor function but have preserved tactile Aβ fibers, may have allodynia that is 
the result of increased and/or incorrect Aβ fiber synapse onto dorsal horn neurons not normally 
receiving those inputs (deafferented allodynic subtype). PHN patients that have lost peripheral 
Aβ nociceptors and do not have mechanical allodynia, may have chronic pain derived from 
central sensitization (deafferented nonallodynic subtype). In a study of PHN patients 25% were 
categorized as resulting from irritable nociceptors, 50% deafferented allodynia, and 25% 
deafferented without allodynia 127. 
Treatments for PHN include first line NSAIDs and antivirals, which have limited efficacy 
when administered past 72 hours post clinical disease; second line antidepressants: amitriptyline, 
desipramine and nortriptyline, and anticonvulsants such as: gabapentin, pregabalin; with the last 
line including topical capsaicin/lidocaine, opioid analgesics, or surgical removal of the affected 
area of skin 30. However, a portion of patients receiving any/all of these interventions will see no 
relief from pain. Leaving a need for new treatments that can address the multiple etiologies 
proposed to explain VZV induced chronic pain. This is not surprising, as PHN results of multiple 
etiologies including neural changes, neuronal death, and ganglionic and peripheral inflammation. 
Importantly, PHN needs to be better understood in order to deliver better treatments. We propose 
this rat model will allow for the investigation of VZV induced pain including its mechanisms. 
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2.0  STATEMENT OF RESEARCH QUESTION AND SPECIFIC AIMS 
Zoster associated pain, particularly the chronic pain state, postherpetic neuralgia, can be 
debilitating and have many consequences as zoster affects the aging population. Current 
treatments do not meet the needs of all Zoster and PHN patients. The goal of this thesis project is 
to better understand the mechanisms underlying VZV-induced pain in a rat model of PHN, and 
to test novel treatment strategies involving the ganglionic expression of pain modulating genes 
from HSV vectors. 
The mechanisms contributing to PHN are complex; more importantly, any current 
treatment may be relatively ineffective in a substantial portion of patients. New treatments have 
been difficult to develop, as VZV species specificity has prevented the animal modeling of 
latency/reactivation cycle. However, the rat model for VZV-induced sensitivity can potentially 
reveal new approaches to treat pain in human patients and uncover the mechanisms underlying 
VZV-induced pain. We show here that Sprague-Dawley rats infected with VZV exhibit 
behaviors indicative of pain upon mechanical and thermal stimulation, which peaks between 4-6 
weeks and spontaneously resolves by 8-10 weeks. My overall hypothesis is VZV-induced 
nocifensive behaviors are due to viral infection and viral gene expression in the 
corresponding dorsal root ganglia. Understanding the role of VZV infection and gene 
expression in the rat model will help define the contribution of the virus to the mechanisms 
underlying VZV-induced pain. Viral gene and protein expression, as well as viral burden have 
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not previously been determined in this model. In addition, we hypothesize that viral gene 
expression is at least partially responsible for the induction of nocifensive behaviors. 
Identification of these genes could lead to second-generation vaccines that, when reactivated, do 
not induce pain and serve as novel targets for pharmaceutical intervention. Third, the rat model 
provides a platform to test new treatment strategies for PHN that can be translated to human 
patients. My specific aims are as follows: 
Specific Aim 1 will correlate viral parameters and changes in host gene 
transcription affecting nocifensive behaviors with its resolution in vivo. VZV is known to be 
highly host restricted, and previously published data indicate that replication of viral DNA is not 
necessary to induce nocifensive behaviors. My results indicated there is a need for viral gene 
expression to induce pain, given UV-inactivated VZV does not generate chronic nocifensive 
behaviors. We investigated viral gene expression, protein localization, and genome copies in the 
ganglion of this model at various time points post inoculation. We have also investigated 
changes in host gene transcription and peripheral nerve innervation. These studies were used to 
address the question, is viral gene expression required to induce pain pathology in this model, 
and what are the effects of viral infection on host gene expression and physiology? 
Specific Aim 2 will evaluate candidate VZV gene deletions to obtain a virus that 
does not generate nocifensive behaviors. We discovered that a virus lacking one of the viral 
kinases, ORF47, does not induce nocifensive behaviors, while knockout of the other viral protein 
kinase, ORF66, did not have an effect on pain. Interestingly, ORF47 delivered to and expressed 
in the DRG using a replication deficient HSV delivery system was shown to induce chronic 
nocifensive behaviors. We have also shown that the kinase activity of ORF47 is necessary for 
both of these phenomena. This strongly suggests kinase activity of ORF47 plays a key role in 
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VZV-induced pain. These studies will indicate the role of viral kinases in pain induction in the 
model. This could establish new targets for treatment of VZV induced pain.  
Specific Aim 3 will assess the use of different treatments for their effect on VZV-
induced nocifensive behaviors. While the rat model has been successfully employed to test the 
effect of pharmaceutical interventions on PHN, we utilized a different strategy and used it to 
evaluate the potential for gene delivery and expression approaches as treatments. We utilized 
replication incompetent HSV vectors to deliver and express modulators of pain as treatments for 
VZV induced pain. We demonstrated that a vector expressing human preproenkephalin (HPPE) 
ablates nocifensive behaviors induced upon VZV infection, in a dose dependent manner. 
Prophylactic inoculation with the HPPE expressing vector also blocked the development of 
nocifensive behaviors post VZV inoculation. This novel treatment could serve as a new, long-
term treatment for human patients suffering from PHN.    
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3.0  GENERAL MATERIALS AND METHODS 
Cells and Viruses. VZV Parent of Oka (pOka) is a low-passage clinical varicella isolate used at 
less than 12 passes following receipt (kind gift from Dr. M. Takahashi (Osaka University, 
Japan)). VZV was grown in the human melanoma cell line MeWo (ATCC, Manassas, VA) using 
Modified Eagles Media (MEM: Life Technologies Inc., Grand Island, NY) supplemented with 
10% fetal bovine serum (FBS) and antibiotic / antimycotic mixture (Sigma, St. Louis, MO). High 
titer VZV was prepared on fresh monolayers of MeWo cells infected at ~0.1 plaque forming 
units (PFU)/cell and harvested at 48-72 h post infection by trypsin digestion when cells showed 
approximately 70-80% cytopathic effect (CPE).  Analyses of the stock virus by immunostaining 
or flow cytometry for VZV surface proteins revealed >90% of the cells were infected. VZV 
viability and infectious titer were maintained by slow-freezing infected cells as aliquots under 
conditions to maintain cell viability (MEM containing 20% FBS and 10% Dimethyl sulfoxide 
(Sigma)) that were stored under liquid nitrogen. Uninfected cell equivalents used as controls 
were treated similarly. VZV titers were determined by plaque assay on MeWo cells.128 
Uninfected cell equivalents used as controls were treated similarly. VZV titers were determined 
by plaque assay on MeWo cells 128,129. Luciferase expressing virus was generated by inserting a 
firefly luciferase (fLuc) cassette with a Zeocin resistance marker onto the C-terminal end of IE63 
in the GS1783 pOka BAC, using techniques previously described 130. Bacterial colonies were 
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selected on Chloramphenicol and Zeocin and, correct insertion of the cassette was verified by 
DNA sequencing. 
ORF66Stop was described previously 128, ORF47stop was a kind gift from Dr. J. Cohen 
131, and ORF47 kinase mutants (47ΔCterm, 47D-N, 47P-S) were a kind gift of Dr. A. Arvin 67. 
Viral ORF47 and ORF9 mutations were generated as described previously using Red mediated 
recombination in bacterial artificial chromosomes containing the entire VZV genome 128,130. A 
kanamycin cassette was used to disrupt the open reading frame of ORF47 and generate point 
mutants E85R and S84A/E85R by recombination. The primers listed below (Table 1) were used 
to PCR amplify the kanamycin resistance cassette (Kanr) from the plasmid pEP-kanS2 and add 
ORF47 and ORF9 flanking sequences required for homologous recombination. The gel-purified 
PCR products were then used to transform the Escherichia coli GS1783 (a kind gift from Dr. G. 
Smith (Northwestern University, Chicago, IL)) containing the pOka VZV BAC and imparts 
chloramphenicol resistance by electroporation. Recombinants were selected by plating on LB 
agar containing 30μg/ml kanamycin and 30μg/ml chloramphenicol and grown at 32C. AvrII or 
HindIII digestion of DNA from individual colonies was used to map the correct insertion of the 
cassette for ORF47 and ORF9 mutants, respectively. In order to make the ORF47 rescuant and 
complete the generation of the ORF9 point mutants, a second round of recombination was 
induced to remove the Kanr  through homologous recombination of repeated sequences flanking 
the Kanr cassette. This was achieved through the induction of the restriction enzyme, I-SceI, in 
liquid cultures containing 1% arabinose, and heated to 42°C for 15 min. Colonies grown at 32°C 
on LB agar containing chloramphenicol and arabinose were checked for loss of the Kanr cassette 
by replica plating individual colonies onto plates containing kanamycin. The BAC DNAs were 
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transfected into MeWo cells using Lipofectamine 2000 (Invitrogen, Carlsbad, CA), and VZV 
plaques were visible after 3 to 5 days of incubation at 35°C.   
Growth kinetics of new viral mutants were completed as detailed in 128. Briefly, 6 well 
plates seeded with MeWo cells were infected with 400pfu/well. Cells from each well were 
dissociated by trypsin digestion and titrated in duplicate onto fresh MeWo cells at each day post 
infection. Plates were stained with gentian violet solution enabling the visualization of plaques 
and syncytia under a dissection scope and the resulting titer calculated. 
UV inactivation of VZV was carried out in 1mL aliquots of virus spread over a 35-mm 
diameter well of a 6-well plate and irradiated using parameters determined empirically from UV 
inactivation kill curves. The light source (Spectronics, Westbury NY) was a 2 x 15W unfiltered 
source emitting UV-C wavelength with intensity of 1550 Joules at 10 inches. Exposures (<15 
min) were timed to result in a reduction of virus titer by >100 fold. Cells were then washed and 
treated for rat inoculation. 
 
HSV Vectors. HSV-1 vectors used here (vHG, HSV47VZV, and HSV47VZV D-N) and vHPPE 
and vHG (detailed previously132) are based on HSV-1 strain KOS 321 and rendered replication 
incompetent by deletion of the essential ICP27 gene and both gene copies of the essential ICP4 
protein. The vector also contains alterations of the promoters of the immediate early ICP22 and 
ICP47 genes so that they are expressed as early or ß-genes. The entire VZV ORF47, 62, 63, and 
66 genes were cloned by PCR, ligated into the vector SASB3, and subsequently transfected with 
vHG infectious viral DNA. HSV47VZV D-N viruses were generated by overlap PCR methods 
that mutated the aspartate of a DYS motif at position 282 in the ORF47 kinase to asparagine. 
Control HSV virus vHG contains two copies of a CMV IE promoter driven enhanced green 
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fluorescent protein (eGFP) gene, followed by a bovine growth hormone polyadenylation signal 
at each ICP4 locus. HSV vector vHPPE was generated from vHG by standard co-transfection-
homologous recombination methods so that the EGFP genes were replaced with cDNA for 
human PPE. Viruses were prepared and titrated in Vero 7b complementing cells expressing the 
ICP4 and ICP27 genes in trans. Control HSV virus vHG contains two copies of a CMV IE 
promoter driven enhanced green fluorescent protein (EGFP) gene, followed by a bovine growth 
hormone polyadenylation signal at each ICP4 locus. HSV vector 47VZV and 47VZV D-N were 
generated from vHG by standard co-transfection-homologous recombination methods so that the 
EGFP genes were replaced with either ORF. HSV vectors were prepared using Vero 7b cells 
grown in infected at an MOI of 0.001. Virus was grown for 24 hr at 37°C followed by 
subsequent growth at 33°C until ~80% CPE. Virus was released from the surface of cells by 
adjusting the entire harvest to 0.45 M NaCl for 3 hr at room temperature. Cellular debris was 
removed by low-speed (3,000 rpm for 5 min) centrifugation and the supernatant filtered using 
0.8µm-filtration units (Thermo-Fisher, Pittsburgh, PA). Virus in the filtrate was concentrated by 
high-speed centrifugation (19,000 rpm for 45 min) and resuspended in 1xPBS (Sigma) 
containing 10% glycerol, aliquoted and stored at –80oC. All HSV vector stocks were verified to 
lack replication competent virus by titration on non-complementing Vero cells, and verified for 
VZV protein expression by western blot. 
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Primers: 
 
Table 1: Primers used to generate mutant viruses 
Virus Primer Sequence 


























Table 2 qPCR primers 
Gene Primer Sequence 
TRADD Forward TCAGCTCATAGTGAACCGGC 
Reverse GATCCCTCAGTGCTCGACAG 
Ntrk2 Forward AGTTTGGCATGAAAGGCCCA 
Reverse CAATGATGACAGCATCGGGC 
TRPV1 Forward TTCACCGAATGGGCCTATGG 
Reverse TGACGGTTAGGGGTCTCACT 
β-Actin Forward CGCGAGTACAACCTTCTTGC 
Reverse CGTCATCCATGGCGAACTGG 
IE62 Forward GACTCCCGACCCTCAGC 
Reverse CATCCGGTGGACACACAGA 
Probe CCGCACGCTCTCTT 
IE63 Forward ATTGAGGCGCCGAATGTTC 
Reverse CTTCACCACCATCATCAGATACG 
Probe TTTGCATAGGAGCGCACTGGAATGTG 
ORF47 Forward GGCTCAAGCGTTGACGTTTT 
Reverse CATTTCACATCTAGGTGGGTCAGG 
Probe CCGCACGTTCGATTTA 
ORF29 Forward GGCGGAACTTTCGTAACCAA 
Reverse CCCCATTAAACAGGTCAACAAAA 
Probe TCCAACCTGTTTTGCGGCGGC 
gC Forward AGTTTGGTTTACGCGTCACCTT 
Reverse CGGTAAATCTGGCATGCGTAT 
Probe ATCCGCACCGTCAACTGGGCA 
ORF21 Forward TGTTGGCATTGCCGTTGA 
Reverse ATAGAAGGACGGTCAGGAACCA 
  32 
Probe CTGCTTCCCCAGCACGTCCGTC 
 
Animal Inoculation. Animals were housed and experimental manipulations on animals 
performed in ABSL-2 facilities approved by the Association for the Accreditation of Laboratory 
Animal Care (AALAC). All procedures were approved by the University of Pittsburgh 
Institutional Animal Care and Use Committee (IACUC).  Male 200-250g Sprague-Dawley rats 
(Charles River Laboratories, Wilmington, MA) were acclimatized to housing for 1 week and 
then assessed for baseline mechanical allodynia (MA) and thermal hyperalgesia (TH) responses, 
as detailed below, to obtain baseline measurements and identify pre-existing atypical responses. 
Following isoflurane-induced anesthesia, 2x105 PFU of cell-associated VZV (or uninfected cell 
equivalents) were injected subcutaneously beneath the plantar surface of the glabrous skin on the 
right hind footpad. Rats were monitored for recovery and return to normal activity. 
Administration of VZV-infected cells, uninfected cells or the maximal dose of HSV vector did 
not induce changes in grooming, self-maintenance and feeding habits or weight loss. After 24h, 
we were unable to observe any significant indication of swelling, inflammation or general 
redness in the ipsilateral injected footpad as compared to the contralateral non-injected hindpaw.  
 
Behavioral Testing. MA was determined using one set of calibrated von Frey filaments 
(Stoetling, Wood Dale, IL) and the “up down” method established previously 133,134. Briefly, 
animals were allowed to equilibrate on a wire grid-based platform apparatus (IITC Life Sciences, 
Woodland Hills, CA) for 15 min. Starting with a von Frey filament of 10g weight of force, each 
filament was applied for 6s with sufficient force to cause bending against the paw when applied 
to one foot at a time. A positive response was defined as rapid withdrawal and/or licking of the 
paw upon application of the stimulus, and was followed by application of the next lower weight 
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von Frey filament. A negative response was followed by testing with the next higher weight von 
Frey filament. A total of 6 measurements were recorded for both left contralateral (uninoculated) 
and right ipsilateral (inoculated) footpads. We imposed a cut off of 150g during the analysis. 
Since some animal to animal variation of sensitivity was occasionally found, MA sensitivity 
variations from animal to animal were minimized by representing responses as a ratio of the 
calculated mean ipsilateral/contralateral response for each animal. MA testing preceded TH 
measurement on the same animal.  TH was determined using a Hargreaves apparatus (IITC) 
according to established methodology.135 Briefly, rats were allowed to equilibrate on a glass 
stage heated to 34oC for at least 15 min. A calibrated focused radiant heat source was placed at a 
set distance under one paw at a time, starting with the contralateral paws, and the time recorded 
for animals to remove their paws in response to the heat source was recorded as the latency 
withdrawal period with a cut-off of 25 seconds. Paw withdrawals due to locomotion or weight 
shifting were not counted, and the trials were repeated. Animals were given 1-2 minute rest 
between measurements and were tested at least three times per paw.  
 
Drug Treatments. DAMGO ([D-Ala2, N-MePhe4, Gly-ol]-enkephalin) and naloxone 
hydrochloride were purchased from Sigma. Rats were first assessed for VZV-induced behavioral 
indicators of pain by MA. Animals then received 20µL injections containing DAMGO 
administered subcutaneously into the footpad at 1 and 10µg per 20µL. Animals were assessed 
for MA measurement at 5, 20 and 60 min post drug administration using von Frey filaments. 
Naloxone treatment studies used animals showing a VZV-induced pain response that had been 
alleviated by HSV vHPPE. These rats were subjected to footpad administration of 5 and 50µg 
total per 20µL of naloxone, followed by similar MA behavioral testing at 5, 20, 60 min and at 24 
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hr post administration. In both studies, control animal groups received each compound without 
prior VZV inoculation, or received PBS into the ipsilateral or contralateral footpad following 
VZV inoculation. All animals underwent identical treatments and handling.   
 
Nucleic acid extraction, purification and quantification. Animals were euthanized at stated 
time points with CO2 and subsequent cardiac puncture. DRGs corresponding to L4,5 were 
removed and snap frozen in liquid nitrogen and placed at -80oC until processing. For DNA, 
DRGs were left in buffer ATL (Qiagen) + proteinase K (Qiagen) solution overnight at 55C. 
DNA was extracted using the DNeasy kit (Qiagen) according to the manufacturers protocol. To 
extract RNA and DNA from the same samples, DRGs were mechanically homogenized in 
TRIzol reagent (Life Technologies Inc., Carlsbad, CA) on a Kinematica PT1200E homogenizer 
(Kinematica, Bohemia, NY) for 7 seconds at ~75% power. Nucleic acids were extracted 
according to manufacturers protocols. DNA pellets were resuspended in Tris EDTA buffer (6.8), 
and RNA in nuclease-free H2O. Viral DNA copies were determined by comparing Ct values 
from tissue to a standard curve spiked with equivalent amount of rat spleen DNA. RNA was 
converted to cDNA using a High Capacity RNA/cDNA Kit (Life Technologies Inc.) following 
manufacturers protocol and subsequently used for qRT-PCR. Gene expression was determined 
by the 2-∆∆Ct method comparing (i) TRADD, Ntrk2, and TRPV1 to β-Actin by SYBR Green; and 
(ii) Calca (Life Technology, Rn00569199_m1), human preproenkephalin (Hs00175049_m1 
Applied Biosystems), or VZV genes (IE62, IE63, ORF47, ORF29, gC, ORF21)136 to GAPDH 
(Life Technology, Rn01775763_g1) by hydrolysis probes.  
RNA for Gene Array analyses was further purified RNeasy Mini kits (Qiagen, Valencia, 
CA).  All nucleic acids were quantified using a Nanodrop Spectrophotometer (Thermo-Fisher, 
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Pittsburgh, PA). Between 150 and 180ng of extracted RNA was processed using a 3’ IVT 
Express Kit (Affymetrix Inc., Santa Clara, CA: catalog # 901228) to yield 49 ± 6 μg of amplified 
RNA (mean ± SD, n = 6).  Between 19 and 20 μg of amplified RNA was hybridized to Rat 230 
2.0 microarrays (Affymetrix, catalog #901228), which were then developed and scanned using 
an Affymetrix GeneChip 3000 Array scanner. Raw data were processed using GCOS v. 1.4 
software (Affymetrix) using  software defaults, except that for change calls the perturbation 
value was changed from 1.1 to 1.05, and the p value from 0.0002 to 0.005. Data exported to 
Microsoft Excel for examination included transcript detectable (Present/Absent) calls and 
pairwise transcript change (Increase/Decrease /No change) calls. For 13,490 unique, 
unambiguously characterized genes all 9 pairwise comparisons were made between the three 
control and three experimental samples. A plausible pairwise change occurred if the sample with 
higher expression was detectable (called Present) and GCOS software made a change call 
(increase or decrease). For 1,674 genes with at least 4 of 9 plausible pairwise changes between 
groups all 6 values were ranked and 344 genes were selected where one group had a rank sum > 
13. This condition requires that the group values were perfectly separated, or that the lowest 
value in the higher expressing group overlapped with the highest value in the lower expressing 
group. Finally, 181 genes were selected for which the mean of all valid pairwise changes was at 
least 1.3 fold. A further 19 genes fulfilled all the above conditions but showed some ambiguity in 
their annotations. Of the total of 200 genes, 86 showed increased expression with VZV while the 
remaining 114 showed decreased expression.  191 were mapped to the Ingenuity Pathway 
Analysis (IPA; build 321501M) database.  
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Luciferase assay. Assays were performed according to manufacturers recommendations 
(Promega Madison, WI). Briefly, cells were scarped off of plates and lysed using 1x freshly 
prepared Reporter Lysis Buffer with one freeze thaw cycle. Lysates were clarified by 
centrifugation at 12,000xg for 2 min at 4oC. Supernatants were stored at -80oC until use. Samples 
were thawed and 20 µL were added to 96-well plates followed by 100 µL of substrate and 
mixed. Luciferase expression was analyzed on 1450 Microbeta plate reader (Perkin Elmer, 
Shelton, CT). Wells containing only lysis buffer were used to establish baseline fluorescence and 
uninfected cells as negative controls. Data presented is normalized to negative controls. 
 
Primary rat tissue culture. Rat tissue was excised from euthanized naïve animals. Lung, kidney 
and glabrous hindpaw skin were removed and placed on ice. Tissue was minced with scissors 
and added to a dissociation solution containing 0.2% Trypsin (Gibco), 0.1% Collagenase 
(Sigma), and 400 mg/mL DNase-I (Qiagen) in Hank’s Buffered Salt Solution-CMF (Gibco). 
Cells were dissociated at 37oC for 30 min, then centrifuged at 5000xg for 5 min at 4oC. This 
process was repeated on pelleted tissue. Dissociated primary cells were plated on 6-well plates 
coated in 0.1% gelatin in Dulbecco’s Modified Eagles Media supplemented with (MEM: Gibco-
Life Technologies Inc.) supplemented with 10% fetal bovine serum (FBS) with antibiotic and 
antimycotics mixture (Sigma). Media was changed the following day to remove contaminating 
red blood cells. 
 
Sections. Animals were euthanized and perfused with formalin. Glabrous footpad skin was 
removed at 10 days post infection and placed in formalin overnight at 4C. Samples were then 
switched from fixative to sucrose and left overnight at 4C. Samples were then positioned in OCT 
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compound (Sakura, Torrance, CA), frozen in liquid nitrogen, and stored at -80C until sectioning. 
Blocks were removed from -80C and sectioned into 30µm sections using a cryostat at -20C.  
 
Immunofluorescence. Cells and sections were stained using established protocols 129. Briefly, 
all samples were fixed in 4% PFA for 15 minutes at room temperature, washed twice with PBS, 
and permeabilized with 0.2% TritonX-100 for 5 min at room temperature. All samples were 
blocked in 10% Heat Inactivated Goat Sera (HIGS) for 1 hr at room temperature. Primary 
antibodies: anti Ku-86 [mouse monoclonal 1:50 dilution (Santa Cruz, Santa Cruz, CA)] and anti 
PGP9.5 [rabbit polyclonal 1:1000 dilution (AbD Serotec, Raleigh, NC)] were diluted in 10% 
HIGS and incubated with tissue overnight at 4oC on a rocking platform. Samples were washed 
three times with PBS + 0.1%Tween-20, secondary antibodies conjugated to Alexafluor 
fluorophores [1:800 dilution (Life Technologies Inc.)] for 1hr at room temperature and 
subsequently washed three time with PBS. Cultured cells were imaged on a Nikon Eclipse 
TE2000-E microscope equipped with a 20x air objective. Nuclei were stained using NucBlue 
Live Cell Stain (Life Technologies Inc.). Sections were imaged on Olympus IX81 FluoView 
1000 confocal microscope (Olympus, Central Valley, PA) with a 20x oil (refractive index 0.85) 
objective. Images were processed in Fiji is ImajeJ (FIJI, open source), where lengths were 
converted from pixel lengths to millimeter. All PGP9.5+ neurites that reached from the dermis 
past the stratum basale layer of the epidermis were counted. 
 
Cell lysates and western blot. Cells were scraped into lysis buffer (50mM Tris, pH7.4, 150mM 
NaCl, 5mM EDTA, 1% Triton X-100) and sonicated for 5 seconds, and finally boiled for 10min. 
Lysates were stored at -20C until needed. 10µl of lysates were run on a 7.5% acrylamide gel at 
70V for 2.5 hours. Protein was transferred to a PVDF membrane (Millipore, Billerica MA) at 
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100V for 1 hour at room temperature. Membrane was then blocked in Odyssey blocking buffer 
(LI-COR, Lincoln NE) overnight at 4C on a rocking platform. Blots were probed for ORF9 
phosphorylated species using an anti ORF9 antibody (rabbit polyclonal diluted to 1:2000 in 
Odyssey blocking buffer) for 1 hour at room temperature on a rocking platform. Membranes 
were then washed three times with 1x Tris buffered saline with 0.1% Tween 20. A secondary 
antibody (goat anti rabbit conjugated to IRDye 800CW (LI-COR) at 1:20,000) was used to detect 
bound primary antibody. Membranes were then washed three times with 1x Tris buffered saline 
with 0.1% Tween 20 and imaged on an Odyssey Imager (LI-COR). 
 
Statistical Analysis. All statistical tests were performed on GraphPad Prism 5 software. All 
curves were plotted and the area under the curve (AUC) calculated for each animal. Mean Area 
Under the Curve was then compared between groups using a One-Way ANOVA with Tukey’s 
multiple comparison test comparing all groups to each other. Individual time points were 
compared using One-Way ANOVA with Dunnett’s multiple comparison test to the specified 
control group. 
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4.0  ANALYSIS OF VZV INFECTION AND GENE EXPRESSION AND EFFECTS VZV 
INFECTION ON THE HOST IN A RAT MODEL OF VZV INDUCED PAIN  
The majority of this chapter will be used as the basis of a manuscript for submission, authored 
by: Jean-Marc G. Guedon, Michael B. Yee, Mingdi Zhang, Stephen A. Harvey, William F. 
Goins, and Paul R. Kinchington. 
TNF soluble receptor data is from an accepted review in the journal Molecular Pain 
authored by Jean-Marc G. Guedon, Joseph C. Glorioso, Paul R. Kinchington, and William F. 
Goins. 
This chapter was written by JGG and PRK with edits from SAH and WFG. All animal 
data was collected and analyzed by JGG with the help of WFG, MZ, and PRK. JGG performed 
all immunohistochemistry and microscopy along with the analysis of that data. MBY generated 
the luciferase and fluorescent viruses, dissociated and analyzed viral infection of primary tissue. 
SAH performed gene array analysis. 
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4.1 ABSTRACT 
Reactivation of the herpesvirus Varicella Zoster Virus (VZV) from a neuronal latent state results 
in herpes zoster, for which the most common complication is pain. Pain associated with acute 
zoster progresses in a significant fraction (>30%) of patients to a more debilitating and protracted 
pain state termed post herpetic neuralgia (PHN). Insights into treatment for pain and PHN have 
been gained from a rat pain model, in which VZV induces prolonged nocifensive behavioral 
indicators of pain following VZV inoculation into the footpad. Here, we address aspects of rat 
permissivity to VZV, viral access to the sensory dorsal root ganglia (DRG) and host cell changes 
that result.  VZV infected primary rat cultures from multiple organs show a post entry block in 
VZV replication with only partial viral gene expression. Nevertheless, rats inoculated with VZV 
show a reduction of peripheral PGP9.5 positive-neurite innervation of the injected ipsilateral paw 
skin not present in contralateral skin or in rats receiving uninfected cells. At the corresponding 
DRG, low levels of VZV DNA were detected, peaking at 5 days post infection and diminishing 
thereafter without detectable virus infectivity. Limited transcription from candidate immediate 
early and early genes was detected. Gene array analyses revealed that changes in host expression 
occurred in ipsilateral DRG of rats exhibiting hypersensitivity, with 84 up regulated and 116 
down regulated genes. These included qRT-PCR validated transcriptional up regulation of 
TRADD, NTRK2, TRPV1, and down regulation of CALCA. With an observed increase in 
immune response factor we also who that VZV-induced hypersensitivity can be partly relieved 
by peripheral inoculation with an HSV vector expressing TNF soluble receptor. These data 
suggest that VZV inoculation into the rat may be abortive, that infection of cutaneous afferents 
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results in viral DNA and gene expression in the DRG soma, and that this expression results in 
peripheral, central, and immunological changes associated with pain signaling. 
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4.2 INTRODUCTION 
Herpes zoster, a painful and debilitating disease most often seen in the elderly and immune 
compromised, is the clinical manifestation of reactivation of the human herpesvirus varicella-
zoster virus (VZV) from a neuronal latent state that was established during the primary infection 
and disease, chickenpox. Zoster affects some quarter of the population in their lifetime with 
incidence rising with age and/or decline of cellular immune status caused by senescence, disease 
or its treatment 27,137.  Of the numerous neurological complications associated with zoster, the 
most common and major cause of morbidity is pain.  Almost all zoster patients suffer some acute 
pain near the timing of skin lesions, with >90% of unvaccinated individuals seeking pain 
alleviating medication 40,137. However, more problematic and difficult-to-treat chronic pain states 
develop in a third of zoster cases, termed post herpetic neuralgia (PHN), which often become 
severe as to lead to disparate secondary consequences that affect quality of life issues, such as 
depression, withdrawal from society, and even suicide.  While there is a vaccine for zoster it is 
only partially effective, reducing zoster incidence by 51% and the “burden of illness” (which 
includes pain and PHN) by 66% 138.  A significant patient fraction have been reported to gain 
little to no relief from any treatment strategy, often at the cost of unwanted side effects.  Most of 
the adult population over 30 in the USA harbor wild-type VZV within their ganglia, and are thus 
at risk for the development of zoster and PHN. The incidence of zoster is increasing and 
therefore it remains an urgent public health need to find the cause of VZV-induced pain and 
PHN, and to develop more effective treatments 139,140. 
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Why zoster is so frequently complicated by pain is not clear, nor is it known why a third 
of zoster cases develop the more protracted pain of PHN.   Studies of human patients have led to 
several theories.  It is clear that reactivation of VZV results in extensive intraganglionic spread 
and involvement of many neurons and satellite cells, which permit the large scale delivery of 
virus to the periphery and the large lesions typical of zoster 30. The resulting inflammation occurs 
not only at the periphery, but also at the ganglia, resulting in a persistent ganglionitis.  
Examination of DRG from cadavers with zoster and PHN at the time of death has suggested that 
zoster results in changes in neuronal anatomy, physiology and circuitry. However, the 
understanding of the VZV-induced chronic pain has been difficult to experimentally investigate 
because the high degree of human species specificity of VZV precludes small animal modeling 
of latency, reactivation and zoster-like disease.    
An exception to modeling of VZV induced disease is the infection of the rat, which has 
been used as a preclinical model of VZV-induced pain. Inoculation of live high titer cell-
associated VZV into the glabrous region of the footpad induces measurable and quantifiable 
nocifensive behaviors of prolonged duration, which partially recapitulate mechanical and thermal 
hypersensitivity seen in many PHN patients. This model has permitted the evaluation of novel as 
well as established pharmacological agents for the treatment of VZV-induced pain 117,118,120,121, 
as well as treatment by ganglionic gene delivery and expression approaches 119.  However, 
virology in the model has not been extensively evaluated. We have previously reported that viral 
gene expression is required for the onset of pain behaviors, and expression of viral proteins in the 
corresponding DRG of the inoculated footpad have been observed 43,109,116-118.  However, the 
level of expression and number of neurons expressing VZV proteins has varied extensively from 
a majority 117,118 to only a small percentage 30.  Intriguingly, two studies report the maintained 
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development of prolonged VZV-induced pain indicators in animals undergoing concurrent 
treatment with high dosing of the antiviral acyclovir from infection, which suggests that VZV 
triggers pain in the model without the need for ongoing viral genomic replication 118,120. This also 
suggests that primary viral infection may initiate changes in the host that are sufficient for the 
development of the prolonged pain response in this model.   
Here we further address this model by evaluating permissivity to VZV infection and the 
changes associated with VZV inoculation in rats and the development of pain-like behaviors.   
We show that primary cell cultures derived from multiple tissues of Sprague-Dawley rats are 
restrictive for full VZV replication, with the block occurring at a post entry stage and after the 
initiation of viral gene expression. VZV inoculation in vivo at rat footpads that normally lead to 
the onset of pain behaviors result in low viral DNA delivery to the corresponding DRG and 
limited gene expression there. However, VZV induces peripheral neurite retraction at the skin 
and also induces changes in the host transcription in DRG that innervate the inoculated footpad. 
These include candidate genes induced in immunity. Accordingly, VZV-induced hypersensitivity 
was reversed in animals that received an HSV vector expressing soluble TNF receptor, but was 
not in those inoculated with a control vector. We conclude that pain in this model is unlikely to 
be the consequence of persistent viral replication in the DRG, but may be the result of prolonged 
changes triggered by abortive viral gene expression events occurring at the periphery and DRG 
upon infection.    
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4.3 RESULTS 
4.3.1 A post-entry block to VZV permissivity in primary rat tissue cultures.  
Animals inoculated with VZV develop hypersensitivity to both mechanical and thermal stimuli 
(Fig 3, thermal data not shown). While the rat model of VZV-induced PHN has been established 
as a preclinical model for testing novel analgesics 117,118,120,121 and treatment strategies involving 
ganglionic delivery of pain modulators 119, no other sign of pathogenesis, skin disease or other 
external clinical sign develops. To our knowledge, there have been no reports of clinical signs 
(other than prolonged sensitivities) in rats inoculated with VZV 26,75,92. Attempts to detect viral 
replication in the inoculated footpad and corresponding DRG, as well as from PBMC fractions 
and spleen, have not proved fruitful (data not shown). We therefore asked if the rat was 
permissive for VZV infection, as it is generally understood that VZV is highly specific for its 
human host. Primary cultures were established from tissues from Sprague Dawley rats, the strain 
used in our VZV pain model studies 119. Cultures were established from glabrous paw skin, lung, 
kidney and DRG, grown to near confluence and infected with VZV by sparse overlay of highly 
infected MeWo cell associated stocks, at a ratio of approximately 1 infected MeWo cell per 300 
uninfected rat primary cells. Primary cultures infected with wild-type VZV showed no plaque 
formation or visible centers of cytopathic effect over 10 days (data not shown). To more closely 
monitor infection, we infected primary cultures with a recombinant dual florescent VZV, in 
which both copies (ORFs 62 and 71) of the gene encoding the immediate early expressed IE62 
transactivator (homologous to HSV ICP4) were tagged with mCherry, and the ORF23 late 
expressed gene encoding the capsid protein (homologous to HSV VP26) was tagged with green 
fluorescent protein (GFP). This dual fluorescent virus replicated in permissive (MeWo and 
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ARPE19) cells  to levels indistinguishable from wild type VZV (data not shown). Live cell 
imaging of the same fields in primary cultures of lung fibroblasts (Fig 4) at 24hpi revealed the 
formation of small foci of RFP and occasionally GFP positivity involving 3-13 cells, suggesting 
VZV can infect rat cell primary tissue monolayers (Fig. 4A).  However, these did not increase in 
size or spread further to other cells by 48 or 96h pi, and started to lose fluorescence by 120hpi. 
Cultures fixed at 96hpi under conditions to maintain reporter fluorescence were co-stained for 
the human specific Ku86 protein to identify input MeWo cells (Fig. 4A).  This revealed that the 
majority of RFP/GFP positive cells in these “microplaques” were not input MeWo cells as they 
did not show Ku86 immunoreactivity, given that most fluorescent cells contained mCherry 
signal, indicative of IE62 gene expression, and only a fraction displayed detectable GFP signal, 
signifying ORF23 expression. We take this to indicate that primary rat cultures can be infected 
by VZV, and some viral gene expression is permitted, but productive replication is blocked and 
prevents further spread.    
 
Figure 3: Sprague-Dawley rats inoculated with VZV become hypersensitive to mechanical stimuli by 
8 days post infection. Animals were pretested prior to infection for baseline MA responses, and then inoculated 
(n=3 per group) at day 0 with 2x105 PFU of pOka (VZV) or uninfected cell equivalents (Control cells). Animals 
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were evaluated for mechanical allodynia (MA) scores depicted as the ratio of ipsilateral to contralateral responses. 
Mean±SEM plotted. This study is representative of multiple similar studies.  
 
To support these data we developed two additional VZV reporter recombinant viruses: 
one in which firefly luciferase (fLuc) was expressed as a “fusion” protein to the ORF63 gene 
encoding the immediate early protein IE63, and a second VZV in which renilla luciferase (rLuc) 
reported the expression of the VZV ORF9 tegument protein.  Our strategy used T2A ribosome 
skipping motifs to permit reporter expression from the native ORF loci and promoters, but as 
separated proteins. The T2A motif results in the VZV protein containing a small 23-residue 
addition to the C terminus, while only a single residue is added to the luciferase reporter, and did 
not affect its enzymatic activity.  These viruses also showed efficient replication in VZV 
permissive cultures at levels similar to wild type virus (data not shown).  In permissive MeWo 
and ARPE19 cells infected with these mutant VZV at 1 infected per 50 uninfected cells, fLuc 
activity reporting expression of VZV IE63 (Fig. 4C) increased over time and showed over a 
hundred fold increase between 4 and 72hpi, representing the amplification and spread of virus in 
the culture. In contrast, fLuc activity in non-permissive murine B6WT3 fibroblasts initially 
showed a burst of expression that only marginally increased over time (Fig. 4C). In rat primary 
cell cultures derived from rat lung and kidney, IE63-reporter activity was similar to that seen in 
B6WT3 cells, and did not undergo the rapid increase reflecting VZV cell-to-cell spread. A more 
dramatic reduction of luciferase activity was seen in rat cultures infected with VZV expressing 
ORF9-reporter. In VZV permissive lines, rLuc activity greatly increased over time, with slightly 
delayed kinetics compared to that for IE63 (Fig. 4D). However in rat cultures, ORF9 reporter 
activity at 18hpi remained at levels similar to input alone. Assessment of viral DNA copies in 
infected rat primary cultures indicated no increase above input, as seen in VZV permissive 
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cultures (Fig. 4E). We take these and the previous results to suggest that rat primary cultures 
support initial infection with some viral gene expression. Similar results were seen in cultures 
established from skin and other tissues (data not shown). These indicate that full productive 
infection is blocked in cells of rat origin, most likely at a stage after the initiation of IE gene 
expression and before viral DNA replication. Thus it appears the rat is not permissive to full 
VZV replication and virus production. 
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 Figure 4:  VZV exhibits infectivity, limited gene expression and no DNA amplification in primary rat 
tissue culture. Primary tissue was excised from naïve rats, dissociated and cultured. Cultures were infected with 500 
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pfu of VZV-63LucZeo and analyzed by live cell microscopy, immunofluorescence, and luciferase activity in cells 
harvested at the various time points shown. (A) VZV infection of primary rat skin fibroblasts. Primary rat tissue 
cultures were infected with 500 pfu of cell-associated VZV expressing fluorescent genes mCherry and GFP tagged 
to both copies of IE62 and ORF23, respectively, were assessed by live cell imaging of the same fields at 24 and 
72hpi. At 96hpi, cultures were fixed and stained for human specific anti-Ku86 (purple) to identify human cell 
inocula under conditions that maintained GFP and mCherry fluorescence. (B) Diagram of luciferase expressing 
VZV. VZV IE63fLuc recombinant virus has firefly luciferase (fLuc) under the control of the native ORF63 
promoter via a T2A ribosomal skipping sequence downstream of ORF63, and ORF9rLuc recombinant virus contains 
renilla luciferase (rLuc) under the control of the ORF9 promoter via a T2A ribosomal skipping sequence. Luciferase 
expression over time in permissive cell lines (MeWo and RPE), non-permissive mouse derived cell line (B6WT3), 
and primary rat tissue cultures (lung and kidney) infected with IE63fLuc (C) or ORF9rLuc (D) are shown. (E) Viral 
copies per 100ng of total extracted DNA from primary rat tissue cultures were determined by qPCR utilizing 
primers directed at ORF29. Input represents cell-associated virus alone, plated at the time of infection and harvest at 
48hpi. These data are representative of two independent experiments. 
4.3.2 Peripheral changes in rats showing pain include a reduced innervating axonal 
density at the glabrous paw skin.   
We then addressed what changes occurred in the rat model after VZV infection that correlate 
with the hypersensitivity that develops. It has been reported that skin biopsies of patients 
suffering from severe PHN exhibit reduced peripheral innervation compared with non-PHN 
zoster patients 141,142.  Rats were therefore inoculated with VZV and allowed to develop MA 
responses as detailed previously, which normally develop within 1 week post inoculation and 
extend beyond 40 days post infection (Fig 3) 30,119. Control uninfected cell inoculated rats or 
those receiving VZV and showing hypersensitivity were sacrificed at 9 dpi and the glabrous 
footpad skin was removed, preserved, cryosectioned at 30-µm and stained for the pan-neuronal 
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marker, PGP9.5. PGP9.5+ neurons that projected from the dermis past the stratum basale layer of 
the epidermis were counted from confocal images of Z-stack projections for each footpad and are 
presented as neurites per millimeter of stratum basale. We observed a reduction in PGP9.5+ 
neurites/mm of stratum basale between control cell inoculated animals (18.92±1.26) and VZV-
infected animals (14.73±1.10) (Fig. 5) with the groups determined to be significantly different by 
the two-tail t-test (p=0.0203). These results were not seen in animals receiving VZV that has 
been inactivated by UV irradiation, which do not develop hypersensitivity pain responses 119. 
These findings indicate that VZV inoculation in the rat induces neurite retraction, similar to that 
reported in human PHN patients, and describes one potential consequence of VZV infection in 
the rat that may contribute to nocifensive behaviors in the rat. 
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 Figure 5: VZV inoculation into rats results in reduced peripheral innervation at the ipsilateral 
footpad. Animals were inoculated with either control cells or VZV-infected cells. At 9 dpi animals were euthanized 
and glabrous hindpaw skin removed and cryosectioned into 30-µm transverse sections. (A) Sections were stained 
with antibody to PGP9.5+ (green) present on neurites and NucBlue live cell stain to identify nuclei (blue). Neurites 
that innervate from the dermis past the stratum basale layer of the epidermis (white line) were counted (white 
arrows). (B) Quantification of PGP9.5+ neurite density (n=3 animals, 4 sections counted /animal) per mm of stratum 
basale interface (length determined by FIJI). Statistical significance determined by two tail unpaired T-test with 
*=p<0.05 [Mean±SEM plotted for B]. 
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4.3.3 VZV DNA accesses the dorsal root ganglia and undergoes limited transcription.   
We then examined changes in the DRG induced by VZV inoculation.  In humans, VZV primary 
infection at the skin results in the infection of axonal termini infiltrating the skin, followed by 
retrograde transport of virus to the ganglia and the onset of a persistent state of latency. While 
our evidence suggests the rat is not fully permissive for VZV infection, we hypothesized that the 
post entry block to replication may still permit the infection of peripherally innervating axons 
from the primary inocula, which may result in changes in gene expression in neurons of the 
dorsal root ganglia.  Rats have been shown to model some aspects of latency, particularly in the 
cotton rat, where VZV DNA is detectable in the corresponding DRG for some periods of time 
75,92,93,114,115,143,144. We first sought to address if VZV reach the DRG by assessing viral genome 
copy numbers in VZV inoculated animals at 2, 5, 7, and 9 days post infection (dpi). L4,5 DRG 
were harvested and nucleic acids extracted from the pooled ganglia. DNA was assayed by 
quantitative PCR for ORF29 and compared to standard curves of known concentrations of VZV 
BAC DNA to establish genome copy number. Viral genome copies could be consistently 
detected in a fraction of infected animals as early as 2 dpi and significant DNA lasted until 9 dpi 
(Fig. 6A). However, detectable genomes were not found above background levels (sensitivity of 
200 genomes/DRG) at 14, 28, 56 dpi (data not shown). These results indicate that VZV does 
access the DRG, but that viral DNA reaching the DRG are low, may be cleared, and do not 
persist at levels above background. Thus the prolonged hypersensitivity seen in the rat following 
VZV inoculation may be the result of VZV induced events that persist after VZV has been 
cleared. 
We next sought to determine if any viral gene expression can be detected at the rat DRG. 
Some groups have suggested there is viral gene expression in DRG of rats by in situ 
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hybridization and immunohistochemistry 43,109,116,117 at various times post infection including the 
products of VZV immediate early (IE) gene 63, IE62 and IE4 in rat ganglia have been reported. 
However, reports of VZV protein expression in latently infected human ganglia have recently 
been clouded and even refuted by indications of cross reactivity of many antibodies with blood 
group antigens 24,145. In the rat, both IE62 and IE63 protein have been reported in very high 
fractions of DRG neurons, which is not consistent with the low numbers of viral genomes 
detected in our work. We thus examined VZV RNA expression of IE62 and IE63 at 2, 5, 7, and 9 
dpi, which represent the two genes that may be expressed in non-permissive rat cultures. No-RT 
controls of the same RNA samples run in parallel showed only minimal DNA contamination, 
establishing that any increase in signal observed were the consequences of amplification of VZV 
RNA. We observed detectable increases in IE62 and IE63 expression at early time points 
compared to control animals and to the reference gene GAPDH.  We also detected some 
expression of candidate VZV early genes, from VZV ORF47 (UL13) and ORF29 (ICP8). 
However, expression of two predicted VZV late genes, including from VZV ORF14 (gC) and 
ORF21 (UL37) were not detectable (Fig 6B). These data indicate that VZV inoculation of the 
rat, most likely results in an abortive axonal infection and the delivery of low levels of viral 
DNA to the DRG. These transmitted genomes undergo a limited level of short-term transcription 
that includes the transcripts for the viral immediate early and possibly early genes.  
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 Figure 6: VZV genome copy number and transcription from ipsilateral innervating dorsal root 
ganglia (DRG) in rats exhibiting VZV induced hypersensitivity. DRG were isolated from naïve animals or 
animals infected with VZV at 2, 5, 7, 9 days post infection (dpi). (A) Viral copy number was determined by SYBR 
green qPCR to ORF29 and back calculated to display copies per L4,5 DRG (n=12 controls, n=8 experimental 
groups). Viral gene expression of genes corresponding to the different kinetic classes including immediate early 
(ORF62, 63), early (ORF47, 29), and late (ORF14, 21) (B) were determined by Taqman qPCR using specific 
primer-probe sets for each gene displayed as 2-∆∆Ct to the GAPDH reference gene (n=3). No RT controls were used 
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to subtract signal due to residual DNA contamination. Dotted line represents “no change” in expression between 
VZV infected and control animals. 
4.3.4 Host gene transcription changes at the ganglia induced by VZV infection.  
Given that our data indicates that VZV inoculation of the footpad results in limited virus access 
the DRG, limited level of gene transcription and induced changes at the periphery, we next 
addressed the possible changes in host gene transcription due to VZV inoculation.  Animals 
inoculated with VZV-infected cells were verified for VZV-induced mechanical and thermal 
hypersensitivity at day 10 dpi, that was not seen in animals receiving control-uninfected cells 
(Fig. 7A). We performed gene array analyses of whole DRG using total RNA from these same 
control and VZV-inoculated animals at 10 dpi.  Animals were sacrificed and L4,5 DRGs were 
removed, and RNA extracted from animals was pooled. Each group represents 2 animals that 
were MeWo injected or VZV-inoculated, with 3 replicates per group. Analysis of the data 
reported over 200 genes were significantly (p>0.001) differentially regulated in the ipsilateral 
DRG of VZV inoculated rats compared with control cell-inoculated animals. A selection of 
differentially expressed genes are shown in figure 7B and C.  VZV infection resulted in 86 genes 
to be up regulated (Fig. 7B) and 114 genes to be down regulated compared to control cell-
inoculated animals (Fig. 7C). Of 13,490 unique, unambiguously characterized genes surveyed by 
the microarray, only 200 satisfied our requirements for ≥ 1.3 fold mean change that was 
statistically viable over the 3 replicates (Fig. 7B and C). Of interest, several genes related to 
immune function and pain were differentially regulated by VZV infection and validated by 
qRTPCR (Fig. 8A,C,E,G) including the TNF receptor associated death domain (TRADD, 
Control Cells 173.5±11.2 and VZV 214.7±1.1 with a fold change of 1.23), neurotrophic tyrosine 
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kinase receptor type 2 (NTRK2 or TrkB, Control Cells 402.6±4.2 and VZV 512.1±29.2 with a 
fold change of 1.27), transient receptor potential cation channel, subfamily V, member 
1 (TRPV1, Control Cells 370.8±19.9 and VZV 458.6±28 with a fold change of 1.24), and 
calcitonin-related polypeptide alpha (CALCA or CGRP, Control Cells 7699±205.6 and VZV 
7024±91.4 with a fold change of 0.87). These fold changes were also confirmed by qRT-PCR to 
the respective sequences to validate gene array analyses (Fig. 8B,D,F,H). Moreover, the 
observed differential regulation of these specific genes sheds light onto the potential mechanisms 
of how VZV might induce pain and the resulting behavioral changes observed in VZV-
inoculated animals, since select genes that overlap those seen here have been shown to be 
differentially regulated during VZV infection in vitro and in rats, as well as in various other pain 
models and are well known pronociceptive genes 146-148. We conclude that VZV induces 
considerable anatomical and transcriptional changes in neuronal cells that correlate with the 
onset of hypersensitivity associated with the development of pain. 
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 Figure 7: Host DRG gene transcription is affected by peripheral VZV inoculation. Animals were 
injected with control cells or VZV-infected cells. (A) At 10 dpi animals infected with VZV had significant changes 
in their mechanical (gram, left panel) and thermal (seconds, right panel) nocifensive paw withdrawal thresholds 
consistent with pain sensation. Affymetrix array analysis heat-map from RNA isolated from these DRGs displays 
genes that were (B) up regulated (red) or (C) down regulated (blue) by VZV infection. Statistics used are two tailed 
t-test *=p<0.05, ***=p<0.01 [Mean±SEM plotted for A and B]. 
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Figure 8: qPCR validation of gene array. Gene array values displayed as relative units (A, C, E, G) and 
qPCR validation displayed as 2-∆∆Ct (B, D, F, H). Results for TRADD (A, B), NTRK2 (C, D), TRPV1 (E, F), and 
CALCA (G, H) are shown [*=p<0.05, ***=p<0.01 Mean±SEM plotted for A and B]. 
4.3.5 VZV inoculated animals treated with a HSV vector expressing TNFα soluble 
receptor exhibit reduced hypersensitivity. 
Since TNFα, IL-1ß and IL-6 are the main pro-inflammatory cytokines secreted by various 
activated immune and glial cells in other models of inflammatory and neuropathic pain 149-154. 
Their alteration in VZV infected DRG suggested a potential role for TNFα signaling in VZV-
induced pain. This provided a new target for intervention of VZV-induced pain. The significant 
increase in immune signaling genes included TRADD and IL7 receptor, further suggesting 
immune signaling during VZV-induced hypersensitivity (Fig. 7). To clarify the role of TNFα in 
VZV-induced pain, we tested HSV vector-mediated expression of the human TNFα soluble 
receptor (sTNFR) for its effects on VZV-induced hypersensitivity. Animals inoculated with VZV 
at day 0 rapidly established robust indicators of hypersensitivity (Fig. 9B and C). Animals were 
treated at day 21 with either control HSV vector (T0ZHG) or HSV expressing sTNFR 
(T0TNFαsR) (Figure 9) at a dose of 108 pfu. Animals inoculated with HSV expressing sTNFR 
showed a rapid and sustained decrease in hypersensitivity within days following T0TNFαsR 
administration, while control vector inoculated animals did not. Mechanical paw withdrawal 
thresholds increased as early as 7 days after HSV sTNFR-expressing vector inoculation and 
lasted until 23 days post HSV vector inoculation (Figure 9B) or 44 days post the introduction of 
VZV-infected cells. However, after 35 days post HSV vector treatment the mechanical 
hypersensitivity began to spontaneously resolve in VZV-infected and untreated animals, as we 
  61 
and others have seen previously 111,116-120. Compared to the effects of vector-mediated sTNFR on 
mechanical pain, thermal relief took longer to respond to sTNFR HSV gene therapy, but the 
response lasted about the same length of time. With the thermal pain response relief started at 23 
days post HSV sTNFR-expressing vector inoculation (44 days post the introduction of VZV-
infected cells) and lasted till 41-dpi after HSV vector injection (Figure 9C). Taken together these 
results indicate that TNFα plays an role in VZV-induced pain and opens up a new target for 
analgesic relief of VZV-induced pain.  
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 Figure 9: Alleviation of VZV-induced hypersensitive nocifensive behaviors by administration of 
TNFα soluble receptor (sTNFR) expressed from a replication defective HSV vector. A diagram of the vectors 
used in this study. All vectors lack ICP27 and ICP4, and contain an expression cassette in the UL41 locus (A). All 
animals (n=4) were infected with VZV at day-0 (B). At 21 days post VZV infection (denoted by arrowheads), 
  63 
animals were inoculated with either HSV sTNFR vector (TNFαsR) or control HSV vector (T0ZHG). Animals were 
monitored for hypersensitivity to (B) mechanical (gram weight) and (C) thermal sensitivity (ratio of 
ipsilateral/contralateral paw withdrawal latencies) and the data is plotted as Mean+SEM. Mean area under the curve 
was calculated for the region represented by brackets for each animal with the Mean±SEM plotted. Statistics 
determined by two-tailed T-test (*=p<0.05, **=p<0.01).  
4.4 DISCUSSION 
The most common descriptive of chronic pain that follows a third of VZV reactivated disease 
and zoster is allodynia,  is defined as hypersensitivity and pain resulting from normally 
innocuous stimuli that does not usually evoke a pain response. Patients develop intense and 
debilitating pain from stimuli such as touch by clothing, hair or gust of wind, that may remain 
painful even after removal of the stimuli. A smaller fraction of PHN patients show increased 
sensitivity to heat or cold. These hypersensitivities are mimicked in rats inoculated with VZV at 
the footpad, which are manifested as measurable decreased paw withdrawal threshold responses 
to mechanical and thermal stimuli. The rat model has been developed in strains Wistar and 
Sprague-Dawley, and have been extensively used to test treatments for alleviation of the chronic 
hypersensitivity 111,116-119,121,155. However, there is a paucity of experiments characterizing the 
virology in the model and what neuronal changes occur that correlate with, and might lead to, 
hypersensitivity after VZV inoculation. Intriguingly, the data presented here suggest that rats are 
not permissive for VZV productive infection, but that the block in viral replication appears to be 
at least partially a post entry event. VZV is generally considered to be highly human specific, 
and most non-primate cells do not support VZV replication. Likewise, and in contrast to HSV-1, 
most small animal models, with the exception of pain in rats and guinea pig reactivation model, 
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show no detectable consequences of VZV infection, disease, or permissivity. The mouse is 
highly refractory to VZV and infection of SCID mice harboring human tissues results in VZV 
only replicating in the human tissue implants 156-158. In the rat, the only sign of infection is the 
prolonged hypersensitivity, so we considered it important to assess rat permissivity to VZV 
infection.  
While primary cultures established from several organs and tissues of the rat did not 
support productive VZV replication or plaque formation, our newly developed reporter viruses 
clearly established that VZV could enter rat primary cells and initiate viral gene expression. We 
showed this by both the production of fluorescent proteins and by the expression of quantifiable 
enzyme activity (Fig 4). However, while VZV may enter and express VZV IE genes in rat cells, 
the work suggests late gene expression minimal or absent. In particular, the promoter activity of 
the late gene encoding the ORF9 tegument protein is remarkably inactive in rat cells (Fig 4D). 
These data suggest the block is perhaps at the stage of viral DNA replication, which would 
effectively limit the maximal expression of VZV late genes. Indeed, we found no increase in 
genome copies after VZV inoculation. This block is reminiscent of VZV in cells of mice and 
hamster origin, where VZV may enter but not efficiently express late proteins 159. The post entry 
block would also be consistent with our work showing that inoculation of animals with UV 
irradiated virus (which would interfere with gene expression) inhibits the development of pain 
indicators 119, but treatment of VZV inoculated rats with high dose acyclovir to block viral DNA 
replication does not stop pain development 116,120. While primary cultures might not fully reflect 
the behavior of VZV in the rat, we have not succeeded in obtaining evidence in vivo of VZV 
replication. Infectious VZV has not been obtained from any rat tissues within 48hr post VZV 
inoculation. Thus, we consider the hypersensitivity that develops to be consequence of those rat 
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host cells that are primarily infected by the human cell-associated input in the inoculum. This 
would almost certainly include infection of peripherally innervating neuronal termini, and is 
supported by our finding that VZV DNA reaches the ipsilateral DRG rapidly after footpad 
inoculation, and undergoes limited gene transcription (Fig 6). Quantitative PCR indicated low 
viral genome copy numbers in the DRG, and RT PCR detected expression of immediate early 
genes 62 and 63 as well as candidate early VZV genes. Other groups have also found VZV DNA 
in rat DRG following peripheral VZV inoculation, although quantification was not undertaken. 
Sadzot-Delvaux et al (1995), found VZV DNA in rat sensory ganglia using in situ hybridization 
out to 7 dpi, similar to our finding of VZV DNA out to 9 dpi 109. However our data suggests total 
genome load is low, at approximately 300 copies per L4,5 DRG. Similar levels are also found in 
the cotton rat “latency” model at 40-50 copies per 500ng of DNA 115,144, within the magnitude 
seen in our studies (DNA yield from rat L4,5 DRG is approximately 3.5-4µg). Regarding viral 
gene expression, we detected quantifiable immediate early gene transcription, which would be 
observed even with a post entry block of viral replication. IE62 and 63 transcripts have been 
found in rat DRG by in situ hybridization and the proteins have been found using 
immunohistochemistry (IHC) by other groups 43,109,111,117,118 However, low ganglionic levels of 
VZV DNA are not consistent with the high fraction of neurons reported as positive for IE62 and 
63 immunostaining. Hasnie et al reported 72-76% of NeuN staining neurons as positive for IE62, 
while Garry et al reported that 82% of peripherin staining neurons were IE62 positive 117,118. We 
consider the values seen by others may be the result of staining problems similar to that 
encountered with the analyses of human ganglionic sections for viral latent proteins 24,145. Our 
recent re-assessment of IE62 using highly absorbed antibodies suggests IE62 immunoreactivity 
only occurs in tens to a few hundred neurons per DRG 30. The IE63 fLuc reporter VZV in the rat 
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shows little to no expression in any tissue in vivo (data not shown). We conclude that VZV can 
infect axonal endings at the periphery, gains access to the DRG, and likely undergoes restricted 
gene expression. This may nevertheless be sufficient to induce the changes associated with the 
development of nocifensive behaviors.   
 While the mechanisms underlying the development of prolonged nocifensive 
behaviors are not yet clear, axonal VZV infection has consequences on neuronal biology. We 
report here the findings that both peripheral and ganglionic changes develop as a result of VZV 
inoculation. At the periphery, we found a significant decrease in PGP9.5+ staining neurites 
extending from the dermis past the stratum basale layer of the epidermis in VZV-infected 
(14.73±1.10/mm stratum basale) compared to rats inoculated with control cells (18.92±1.26/mm 
stratum basale) (Fig 5). These findings echo similar findings in human patients, where there was 
significantly reduced peripheral innervation at the skin of the affected dermatome in zoster 
patients, and even further reduced innervation when the patients are experiencing PHN 141,142,160. 
Normal human innervation levels of around 2000 neurites/mm2 were reduced in zoster patients to 
mean innervation density of 1569±230 neurites/mm2, while innervation densities in PHN patients 
were further reduced to 337±92 neurites/mm2 141. Thus the rat model appears to mirror aspects of 
human zoster and PHN associated changes in peripheral neuron physiology. However it remains 
to be resolved whether such changes are the result of viral infection at the periphery affecting 
neurites directly, or neurite retraction is a consequence of VZV induced changes exerted at the 
sensory ganglia.  
We documented changes in host gene expression to establish the platform upon which 
nocifensive indicators of pain might develop. Using gene array analysis on 10 dpi whole L4,5 
dorsal root ganglia from animals exhibiting hypersensitivity to mechanical stimuli, we observed 
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200 genes that were differentially regulated upon VZV infection (Fig 7 and 8). While altered 
levels of expression reporting from the arrays were not high, they likely reflect a small number 
of neurons in a large pool of unaffected cells of the ganglia, and were statistically significant 
based on multiple parallel samples. Of the genes affected, we found evidence of alterations in the 
TNF signaling cascade, especially TRADD and TNFsrf21 similar to that observed in the SCID-
hu-VZV infection mouse model (Fig 8) 147. In addition, we also observed changes in the 
expression of several genes previously shown to play a role in nociception consistent with other 
chronic pain models, such as the HIV gp120-induced neuropathic pain model 148. Maratou et al 
observed an increase in TRPV1, NTRK2 (TrkB) isoforms and down-regulation in CALCA gene 
expression in animals experiencing HIV gp120-induced pain compared to sham rats 148. We 
observed a similar increase in TRPV1, NTRK2, and a down-regulation of CALCA in VZV-
infected compared to control cell-injected animals (Fig 8). Our data fits with Maratou et al and 
suggests that virally induced neuropathic pain may activate similar pathways or at least result in 
similar downstream changes in nociceptive genes. Thus, the changes seen are consistent with a 
VZV induced pain state.   
Lastly we tested an HSV vector that expresses soluble TNF receptor for its effect on 
VZV-induced hypersensitivity in rats. Such vectors have been shown to be effective in other pain 
models including the rat L5 spinal nerve ligation (SNL) model 161, the T11-T12 laminectomy 
spinal cord injury (SCI) model 162, the resiniferatoxin (RTx)-induced model of bladder 
nociception 163 as well as HIV gp120-induced neuropathic pain 164. VZV inoculated animals that 
had established mechanical hypersensitivity and were inoculated with a vector expressing TNF 
soluble receptor had immediate and sustained relief from mechanical hypersensitivity and, while 
it took longer, thermal stimuli. Interestingly mean area under the curve plots suggested that not 
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all animals responded to treatment. These data suggest that some PHN patients may be predicted 
to respond to biologics that target TNFα, a key inflammatory component. However, some severe 
complications due to reactivated VZV seen in rheumatoid arthritis (RA), inflammatory bowel 
disease (IBD), Crohn’s disease, ankylosing spondylitis, plaque psoriasis, and psoriatic arthritis 
patients receiving anti-TNF treatments to reduce the host immune response suggests that whole-
body treatment by anti-TNF injectable biologics may not be an optimal therapy for all PHN 
patients 165-172. 
Taken together with our previous data, we conclude that VZV footpad inoculation results 
in a limited, non-productive infection of rat tissue that is not capable of spreading throughout the 
host by productive amplification. Rather, the self-limiting infection results in a limited gene 
expression program in vivo, which appears sufficient to induce the nocifensive responses. 
However, such infections probably include infection of axonal termini, and ganglionic delivery 
of low levels of viral DNA. However, VZV infection of the host DRG results in changes in host 
gene transcription for genes involved in immune recognition and nociception that may also be 
involved in the corresponding neurite retraction that is observed. We have also shown that site 
directed interference of TNF signaling results in quantifiable relief of VZV-induced pain in rats. 
What remains to be determined is the length of time needed for the neurons to properly re-
innervate the periphery, if at all, which subtypes of neurons are affected, and which specific 
VZV genes are involved in these processes.  
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5.0  ORF47 IS NECESSARY AND SUFFICIENT TO GENERATE HYPERSENSITIVITY IN 
A RODENT MODEL OF POSTHERPETIC NEURALGIA 
This chapter will be used as the basis of a manuscript for submission, authored by: Jean-Marc G. 
Guedon, William F. Goins, Michael B. Yee, Emily A. Scott, Mingdi Zhang, Paul R. Kinchington 
This chapter was written by JGG and PRK. All animal data was collected and analyzed 
by JGG with the help of WFG, MZ, and PRK. MBY, EAS, and JGG generated the mutant 
viruses reported here. JGG performed immunohistochemistry and microscopy along with all the 
analysis. EAS and JGG performed western blot, sequence confirmation of mutants, and in vitro 
growth curve analysis. 
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5.1 INTRODUCTION: 
Varicella Zoster Virus (VZV) is the causative agent of chickenpox upon primary infection and 
herpes zoster upon reactivation from latency that was established in neurons in sensory ganglia 
along the entire neuraxis. Unlike primary infection, zoster (or shingles) is almost always 
associated with pain, with greater than 90% of patients seeking medication to alleviate pain. 
Between 10-30% of patients go on to develop a chronic, long lasting pain state known as Post 
Herpetic Neuralgia (PHN). PHN patients generally describe three forms of pain, with the most 
common and distressing being allodynia, or pain from otherwise innocuous stimuli. VZV 
reactivation and its consequences have proved difficult to study as VZV is highly species 
specific and there is no small animal model of zoster or reactivation. However, there exists a rat 
model of VZV-induced pain that appears to recapitulate the allodynia observed in PHN patients. 
This model of VZV-induced pain has been established in rats and manifests as a chronic 
hypersensitivity similar to that observed during PHN 111. Viral transcription/infection, but not 
DNA replication, appears to be required for VZV-induced hypersensitivity 117,119,120. We have 
found that viral gene expression appears to be limited to immediate early and early genes, and 
expression of late genes is undetectable in vivo (Chapter 4). These data suggest that protein(s) 
from immediate early or early expressed gene may be responsible for inducing pain. However, 
viral infection does affect host gene transcription in whole ganglia and reduces peripheral 
innervation in the rat. This loss of peripherally innervating neurites has been documented in 
Zoster and is markedly lower in PHN patients when compared with either zoster, which have 
reduced innervation compared to healthy controls. 
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Here we evaluate the two virally encoded, early expressed, serine/threonine kinases 
ORF47 and ORF66 for their role in VZV-induced pain. Both virally encoded protein kinases are 
dispensable for viral growth in vitro, but both are known to be necessary for different stages of in 
vivo spread. The ORF47 kinase is acidophilic with a consensus phosphorylation motif similar to 
human casein kinase II. A deduced motif of: S/T-X-D/E-D/E has been identified with a 
preference for acidic amino acids -1 or +1 173. The kinase appears to have orthologs in all 
herpesviruses, and is similar to the UL13 kinase of HSV1 The targets for ORF47 have not been 
fully elucidated, but it is known to phosphorylate several viral proteins including: itself, IE62 
(the major transactivators of viral gene expression), ORF9 (a tegument protein), and ORF32 
131,174,175. The only known host target is IRF3, but it seems likely there are others176.  
The second viral kinase, encoded by ORF66, is a serine/threonine kinase that is the VZV 
ortholog to HSV1 and PRV US3, a kinase that is conserved among the alphaherpesviruses. 
ORF66 is a basophilic kinase with a target serine preceded by lysines and/or arginines 177. 
ORF66 has several known targets including itself, IE62, Matrin 3, and HDAC 1 and 2 128,178-180. 
The target motif of ORF66 overlaps with protein kinase A. Viruses deficient in ORF66 exhibit 
reduced growth in T cells and corneal fibroblasts in vitro 128,181.  
Both kinases are necessary for growth in certain cells in vivo. ORF47 is necessary for 
productive viral growth in T cells and skin in the SCID-hu model and an ex vivo model of human 
T cell VZV infection, as well as for transferring infection from dendritic cells to susceptible 
fibroblasts 158,181,182. Loss of ORF47 kinase function results in aberrant capsid formation that 
results in decreased cell free spread in vivo 67,182,183. ORF66 is needed for efficient viral 
replication in T cells in a SCID-hu model but has only a slight reduction in growth in skin 184,185. 
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Therefore, while both kinases are dispensable for viral growth in vitro, but clearly affect 
virulence in vivo. 
ORF9 is a late expressed, tegument-associated gene that is essential for viral growth 
186,187. During infection, transcripts from the ORF9 gene are readily detected and when 
quantified, are the most abundant viral transcripts 188,189. ORF9 is the ortholog of HSV1 UL49 
and shares homology with the UL49 encoded protein, VP22 of HSV1. ORF9 interacts 
extensively with viral proteins including IE62, gE, gI, gH, gN, ORF15, ORF23, ORF38, and 
ORF47 186,190-193. These extensive interactions likely make ORF9 important in proper tegument 
and virion formation, as ORF9 hyperphosphorylation (mediated by ORF47 at Serine 84) 
influences virion formation and egress 193. 
Here we demonstrate the ORF47 gene product is both necessary and sufficient for the 
induction of hypersensitivity in animals. Particularly, mutants in the kinase domain affect the 
induction of pain by VZV. We also investigated mechanisms for this hypersensitivity and show 
that infection of rats with wild-type VZV reduces peripheral nerve innervation but this trend is 
reversed when ORF47 is not present. Interestingly, animals inoculated with an ORF9 
phosphorylation mutant that alters the consensus site for ORF47 mediated phosphorylation at 
position 85 only generates partial hypersensitivity. Together these data suggest that ORF47 is 
required for pain induction, which is partly due to its role in phosphorylation of ORF9. 
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5.2 RESULTS 
5.2.1 ORF47 kinase activity is necessary for induction of hypersensitivity.  
Protein kinases play an important role in cell signaling and many are known to be involved in 
propagating pain signals; therefore we focused on identifying the role of the two VZV encoded 
protein serine/threonine kinases in VZV-induced pain. Varicella zoster virus encodes two 
serine/threonine kinases, open reading frames 47 and 66, and VZV deficient for either gene 
product have been previously described 128,131. We first assessed VZV with mutations for either 
ORF47 or ORF66 to inoculate animals and compare the hypersensitivity that develops to wild 
type VZV and controls. Rats received 2x105pfu or control uninfected cells into the right hind 
footpad and were tested for behavioral hypersensitivity to mechanical and thermal stimuli. 
Animals inoculated with wild type VZV developed markedly lower tolerances to both 
mechanical and thermal stimuli, when compared to baseline or control cell inoculated animals 
(Figure 10). Rats inoculated with ORF66stop exhibited hypersensitivity similar to wild type 
VZV beginning at 5dpi and self-resolving at 53dpi (Fig 10A and D). However, animals injected 
with two different ORF47 mutants did not develop hypersensitivity to either mechanical or 
thermal stimuli (Figure 10B and E). The two ORF47 mutants represented one detailed previously 
(Cohen 47), and one that we generated in which ORF47 was disrupted by a kanamycin resistance 
cassette. However, animals receiving VZV in which the ORF47 gene was restored by removal of 
the kanamycin resistance cassette, induced responses similar to wild type VZV and ORF66stop. 
Together these data suggest that ORF47 is necessary for induction of VZV-induced 
hypersensitivity. 
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 Figure 10: ORF47 but not ORF66 is necessary for VZV induced pain in rats. Animals were tested for 
baseline responses at -1 and 0 days post infection, inoculated with control cell equivalents, VZV (pOka), 
ORF66Stop, ORF47Stop, ORF47Kan, or ORF47Rescuant (n=5). Animals were tested for sensitivity to mechanical 
(A-C) and thermal (D-F) sensitivity. Data presented is representative of two independent experiments and the 
Mean±SEM plotted. Lines that overlap were shifted slightly up to be visible. Mean Area under the curve plotted for 
all animals Mean±SEM. Statistics used: (A,B, D, E) One-Way ANOVA with Dunnett’s multiple comparison test 
comparing MeWo to all groups (C and F) One-Way ANOVA with Dunnett’s multiple comparison test comparing 
pOka to all other groups. *=p<0.01, ***=p<0.001. 
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5.2.2 VZV with Mutations in the ORF47 kinase domain also do not develop 
hypersensitivity in rats.  
To further delineate the functions of ORF47 that are necessary for pain induction, we tested a 
series of previously detailed mutants that are either deleted most of the C-terminal kinase domain 
(ΔCterm), or contain a point mutation in the ATP-binding domain (D-N), or a tertiary structural 
motif (P-S) 67. All three mutants, along with the parental vaccine Oka were used to inoculate 
animals to evaluate their effects on VZV-induced hypersensitivity. Animals inoculated with 
vaccine Oka developed mechanical hypersensitivity by 7dpi that spontaneously resolved by 
31dpi.  The shortened duration of hypersensitivity differs from previous studies (Figure 10) and 
may have been due to the use of an attenuated strain. Animals that received viruses with any 
mutation in the kinase domain did not develop mechanical hypersensitivity at any point during 
the experiment (Figure 11). Thermal hypersensitivity followed a similar trend but was not 
statistically different between the groups (data not shown). These data suggest that kinase 
activity necessary for the induction of pain, and that proper folding of the kinase domain may 
also be necessary. 
 
Figure 11: ORF47 kinase domain mutants do not induce nocifensive behaviors in VZV inoculated 
rats. Animals were evaluated for baseline responses at 0dpi and then inoculated with either vOka, vOka 47∆Cterm 
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(truncated after amino acid 267), vOka 47D-N (at amino acid 283), or vOka P-S (at amino acid 333) (n=4). Animals 
were subsequently evaluated for mechanical sensitivity (A and B). This data is representative of two independent 
experiments and shows Mean±SEM plotted. Lines that overlap were shifted up to be visible. Mean Area under the 
curve plotted for all animals Mean±SEM. Statistics used (A) One-Way ANOVA with Dunnett’s multiple 
comparison test comparing vOka 47∆Cterm to all groups (B) One-Way ANOVA with Dunnett’s multiple 
comparison test with vOka GFP being the control column. *=p<0.01, ***=p<0.001. 
5.2.3 HSV vector delivered VZV ORF47 is sufficient to generate nocifensive behaviors.  
To establish whether ORF47 is sufficient to induce hypersensitivity, we utilized an HSV vector 
to express ORF47. The coding sequence from VZV ORF47 was engineered into a replication 
incompetent HSV vector at both of the ICP4 loci in a vector background shown to deliver and 
express genes to ganglia and that we have used to treat VZV-induced pain (Chapter 6). Animals 
injected with the control HSV vector did not develop nocifensive behaviors, but animals injected 
with HSV47VZV developed both mechanical and thermal hypersensitivity within 4 and 8 days 
post infection, respectively (Figure 12). Animals exhibited significantly reduced withdrawal 
thresholds at several time points (indicated by asterisks) and differences between mean area 
under the curve were also significantly reduced in HSV47VZV infected animals compared with 
control-injected animals. This suggests that expression of ORF47 outside the context of VZV 
infection is sufficient to generate hypersensitivity. 
To further confirm the role of ORF47 kinase activity in the induction of pain, we 
developed an HSV vector which expressed ORF47 of VZV with a point mutation at amino acid 
283 changed the aspartate to an asparagine (D-N) in the ATP binding domain of the kinase that 
ablates kinase activity. When administered to animals, HSV47VZVD-N did not induce 
nocifensive behaviors and animals exhibited no change in mechanical or thermal sensitivity 
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when compared with parental vHG control (Figure 12). These data support our conclusion that 
VZV ORF47 is both necessary and sufficient to induce nocifensive behaviors in animals, and 
that kinase activity is necessary for the development of hypersensitivity.  
 
Figure 12: HSV replication incompetent vectors expressing VZV ORF47 generate nocifensive 
behaviors when inoculated into rats. Baseline behavioral measurements were taken 3days before inoculation and 
then at intervals after. Animals were injected with 108pfu at day 0 with either vHG, HSV 47VZV or HSV 47D-N 
VZV (n=4) (A and C). Data is representative of two independent experiments and the Mean±SEM plotted (B and 
D). Lines that overlap were shifted up to be visible. Mean Area under the curve plotted for all animals Mean±SEM. 
Statistics (A and C) One-Way ANOVA with Dunnett’s multiple comparison test comparing HSV GFP to all groups, 
(B and D) One-Way ANOVA with Dunnett’s multiple comparison test with HSV GFP being the control column. 
*=p<0.01, ***=p<0.001. 
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5.2.4 Loss of peripheral neurite innervation upon VZV inoculation is reversed in animals 
inoculated with ORF47 mutants.  
Humans with zoster and PHN have been reported to have reduced peripheral innervation of the 
affected skin 141,160. This observation is replicated in rats inoculated with VZV, which also have a 
significant reduction in peripheral innervation of PGP9.5+ neurites at day 10-post infection 
(Chapter 4). We therefore investigated whether this reduction also occurred in animals 
inoculated with ORF47 mutant viruses. Animals inoculated with control cells, VZV, 47Kan, or 
47Rescuant were allowed to develop hypersensitivity and at 13dpi, animals were sacrificed, 
ipsilateral glabrous skin was removed, preserved, cryosectioned, and stained for the pan-neuronal 
marker, PGP9.5. Neurites stained by PGP9.5 that project past the stratum basale layer of the 
epidermis were counted and are plotted here as PGP9.5+ neurites/mm of the stratum basale. As 
expected, animals inoculated with wild type VZV (pOka) (mean ± standard error = 9.53±0.69) 
and ORF47Rescuant (9.72±0.88) which both developed pain had a significant reduction in 
PGP9.5+ neurites/mm compared to control cell inoculated animals (12.97±0.75) (Figure 13). 
Importantly, animals inoculated with ORF47Kan (15.41±0.92) did not develop a reduction in 
peripheral neurites. Thus reduction in peripheral innervation correlates with hypersensitivity in 
animals, and in the converse, a lack of reduction in peripheral innervation correlates with no 
change in sensitivity to stimuli.  
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 Figure 13: Peripheral neurite retraction induced by VZV and 47Rescuant but not ORF47KO virus. 
Animals were inoculated with control cells, pOka, pOka 47Kan, or 47Rescuant. At 13dpi, when animals developed 
hypersensitivity to mechanical and thermal stimuli, animals were sacrificed and glabrous paw skin was removed. 
Skin was cryosectioned in 30µm slices and stained with PGP9.5 (green) and Hoechst (blue) (A). White line 
represents the border between the stratum basale and stratum spinosum layers of the epidermis. White arrows denote 
neurites that innervate past the stratum basale layer of the epidermis. (B) Quantification of neurite density (n=4 per 
group total of 20 sections counted, 5 sections per animal) Statistics One-Way ANOVA with Tukey’s multiple 
comparison test comparing all columns. *=p<0.01, ***=p<0.001. 
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5.2.5 ORF47 and ORF9 mutant virus generation and growth kinetics in vitro.  
An important viral target of ORF47 is ORF9, which has been shown to interact with several 
tegument associated proteins and glycoproteins. This interaction is direct, and leads to the 
phosphorylation of ORF9, which is important in viral assembly and egress. Interestingly, mutant 
viruses that do not express the ORF47 kinase appear morphologically similar to viruses that 
express a mutant ORF9 that has an altered ORF47 phosphorylation target site at amino acid 84. 
It has been shown that ORF47 mediated phosphorylation of ORF9 is necessary for proper virion 
formation and both exhibit defects in virus assembly and egress 193. We therefore asked if the 
lack of hypersensitivity in animals inoculated with ORF47 mutant viruses is the result of 
phosphorylation of ORF9 protein by the ORF47 kinase. To address this question, we generated 
two VZV mutants that disrupted ORF9 protein phosphorylation at position 84 (ORF9 E85R and 
ORF9 S84A E85R). Both mutants were VZV BAC derived and verified to be correct by 
sequencing and restriction enzyme mapping (Fig. 14A). Mutant viruses were analyzed for their 
growth characteristics in MeWo cells (Figure 14B) and while we observed a slight reduction in 
the growth of ORF47Kan and ORF9 S84A E85S, compared to wild type VZV (pOka), all 
replicated robustly in this cell type 
 We subsequently analyzed ORF47 kinase function and mutation of the ORF9 
phosphorylation sites by immunoblot. Cells were infected with 500pfu of wild type VZV (pOka), 
47Rescuant, 47Kan, ORF9 E85R, or ORF9 S84A E85R and lysates were made at 24-hour post 
infection, and probed for ORF9 protein and its phosphorylation species. Analysis revealed that 
wild type pOka and 47Rescuant have a substantial portion of ORF9 that is hyperphosphorylated 
and migrates slower in the gel.. However 47Kan and both ORF9 mutants have little to no 
hyperphosphorylated ORF9 species. Mutations in ORF47 and ORF9 did not drastically affect 
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viral growth in vitro and both mutations, as expected, result in decreased hyperphosphorylation 
of ORF9. 
 
Figure 14: ORF47 knock out mutant growth characteristics and expression. ORF47 was disrupted by 
the insertion of a kanamycin resistance cassette into the open reading frame of ORF47 (A). Growth curve analysis of 
ORF47 knock out and ORF9 phosphorylation mutant viruses in MeWo cells (B). Western blot analysis of ORF9 
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phosphorylation (using an polyclonal ORF9 specific antibody) as a surrogate for ORF47 activity and to confirm the 
mutation of the ORF9 phosphorylation site at position 84 abrogated ORF9 phosphorylation by ORF47 (C). 
5.2.6 ORF9 phosphorylation mutants exhibit modulated pain response in vivo. 
We then tested whether the VZV mutations that affect hyperphosphorylation of ORF9 by ORF47 
induced hypersensitivity in animals. Animals were inoculated with control cells, wild type VZV, 
or mutant viruses, subcutaneously, under the glabrous skin of animals and were subsequently 
tested for sensitivity to mechanical and thermal stimuli. Wild type VZV inoculated animals 
developed the characteristic hypersensitivity to mechanical and thermal stimuli by 14 and 17 dpi. 
As before, 47Kan inoculated animals did not develop signs of hypersensitivity at any point either 
to mechanical or thermal stimuli (Fig 15A-D). Interestingly, mutants that altered ORF9 
hyperphosphorylation showed two different effects. Animals inoculated with ORF9 E85R, a 
more conservative alteration to the consensus ORF47 phosphorylation site at ORF9, exhibited 
transient mechanical hypersensitivity at 9dpi that resolved and did not return (Figure 15). 
However, animals inoculated with a more extensive disruption of the phosphorylation site, ORF9 
S84A E85R that mutates the serine at position 84, developed hypersensitivity at 7dpi that lasted 
in only one animal for the duration of the experiment while the other animals displayed 
hypersensitivity at 7dpi that resolved, but then returned  (at 29 and 35dpi) (Figure 15A). Thermal 
hypersensitivity, while less robust, does not show any transient hypersensitivity at 7dpi, but does 
show the same trend with mean area under the curve of ORF9 E85R more similar to 47Kan, and 
ORF9 S84A E85R displaying an intermediate phenotype (Figure 15D). These data imply that the 
ORF9 phosphorylation, which is necessary for proper virus assembly, may be a contributing 
factor to VZV-induced hypersensitivity in animals. At this stage we cannot fully explain the 
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intermediate phenotype seen in VZV ORF9 S84A E85R inoculated animals. This is preliminary 
work that will be repeated. 
  
Figure 15: ORF9 phosphorylation mutants affect VZV-induced pain in animals. Animals (n=5 per 
group) were inoculated with VZV, 47Kan, ORF9 E85R, or ORF9 S84A E85R at 0dpi. Animals were tested for 
sensitivity to mechanical (A) and thermal (B) stimuli. Mean±SEM plotted (C and D). Mean area under the curve 
plotted for each animal. Statistics used: Statistics (A and B) One-Way ANOVA with Dunnett’s multiple comparison 
test comparing 47Kan to all groups, (C and D) One-Way ANOVA with Tukey’s post test comparing all columns. 
*=p<0.01, ***=p<0.001. 
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5.3 DISCUSSION 
ORF47 is one of two viral serine/threonine kinases and has a consensus phosphorylation target 
site sequence similar to Casein Kinase II 194. The kinase is homologous to that of HSV UL13, 
which is conserved among α, β, and γ herpesviruses 61. ORF47 is not necessary for viral growth 
in vitro, and appears to not be required for the establishment of latency in rodents 131,144. 
However, ORF47 is necessary for in vivo infection of T cells and skin 67,183. The kinase is also 
required for infection of immature dendritic cells (DC) and in the transfer of infection from these 
DCs to permissive melanoma cells 182. Here we show that ORF47 is necessary to generate pain 
in the rat model of PHN. This is not a general feature of viral kinases since the other viral protein 
kinase, ORF66, is not necessary for VZV induction of pain. Two different ORF47 mutants were 
utilized: ORF47Kan that was derived in a BAC using Red-mediated recombination to insert a 
kanamycin resistance cassette into ORF47, while the second virus is ORF47stop (a kind gift 
from J. Cohen), which was cosmid derived and has two stop codons inserted into ORF47 131. 
Both viruses showed the same reduction in hypersensitivity, confirming the necessity for ORF47 
for the induction of hypersensitivity. This is the first report of a Varicella Zoster Virus gene 
involved in the induction of nocifensive behaviors and pain, and is only the second viral protein 
discovered to be involved in pain, the other being HIV gp120 195. Unlike ORF47, gp120 is a 
surface protein that is essential for HIV binding and entry into susceptible cells 196. When gp120 
is injected into the footpad or applied epineurally or intrathecally, animals become chronically 
hypersensitive to stimuli 195,197-199. This phenomenon is at least partially derived from neuronal 
injury and death, resulting in the release of proinflammatory cytokines (interleukin 1, interleukin 
6, and tumor necrosis factor α) and chemokines (chemokine C-C ligand 5 also known as 
RANTES and monocyte-chemoattracting protein 1) 195,200-203 as shown in chapter 4. VZV may 
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also instigate pain, through injury and maintain pain through a neuro-immune interaction. We 
have shown previously that VZV infection reduces peripheral innervation, increases TRADD 
transcription, and treatment of VZV-hypersensitive animals with an HSV vector expressing 
soluble TNF receptor alleviates hypersensitivity (Chapter 4). This hypothesis of immune 
mediated pain during VZV infection is intriguing but requires further study. 
There are two main functional domains of ORF47, C terminal kinase activity and N 
terminal domain involved in protein binding to the viral regulatory protein IE62 67. Here we 
utilize previously published C terminal mutants to discern the role of kinase activity for the 
induction of pain 67. 47ΔCterm expresses a truncated form of ORF47 with all amino acids after 
226 removed and 47D-N has a mutated ATP binding site at amino acid 283 (from DYS to NYS). 
Both of these mutants affect ORF47 kinase activity and pathogenesis in skin and T cells 67,183. 
The 47P-S mutant has a substitution in the ORF47 APE tertiary folding motif at amino acid 333 
(from PPE in VZV to SPE), but this does not affect kinase activity or pathogenesis in skin 67. We 
show that mutations in the kinase domain that affect kinase activity do not induce 
hypersensitivity in animals. Animals inoculated with HSV 47D-N VZV also do not develop 
nocifensive behaviors, where as animals inoculated with HSV 47 VZV did. Together, these data 
imply that ORF47 kinase function is necessary for pain induction. Unexpectedly, animals 
inoculated with a 47P-S mutant virus do not exhibit nocifensive behaviors. Intriguingly, 47P-S 
mutation does not affect either kinase activity or skin pathogenesis because this mutation was 
designed to alter a tertiary folding motif in the kinase domain, but not directly ablate kinase 
function. This perturbation may result in a folding defect that slightly changes the kinase in a 
way that it no longer phosphorylates the host and viral targets that mediate VZV-induced pain 
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responses. 47P-S may also affect some yet unknown function of the C terminus of ORF47 that 
requires correct folding.  
Peripheral nerve retraction in VZV inoculated animals replicates a hallmark of PHN and 
zoster in human patients 141,142,160. It is clear that both hypersensitive rats and PHN patients have 
a significant retraction of peripheral nerve fibers. This retraction is not present in animals 
inoculated with an ORF47Kan virus, but is in ORF47Rescuant infected animals. The retraction 
of peripheral neurites may help explain the long-term hypersensitivity observed in rats. This 
hypothesis requires further investigation in animals that have had their hypersensitivity resolve 
naturally. Intriguingly, each virus would be expected to induce a localized immune response at 
the peripheral site of injection, similar to wild type VZV. As such this may exclude peripheral 
immune responses as contributing to the hypersensitivity. 
Lastly, we investigated one possible mechanism of ORF47 mediated hypersensitivity in 
rats by examining a known target of ORF47, the tegument protein ORF9. We generated two 
mutants that alter the ORF47 phosphorylation target site in ORF9: one alters the phosphorylation 
site from SEDD to SRDD by replacing the glutamate at position 85 with an arginine (ORF9 
E85R); the other alters both the serine and glutamate to an alanine and arginine (ORF9 S84A 
E85R). The viruses generated were reported to be morphologically similar to those generated by 
ORF47 deletion mutants, as ORF9 E85R increases defective virus formation and reduces 
extracellular viruses 193. It was proposed that the phosphorylation of ORF9 affects viral tegument 
assembly at the transgolgi network 193. Here we show that both mutations result in a reduction in 
hyperphosphorylation and that the ORF9 S84A E85R mutant virus has only a slight reduction in 
growth in vitro. We hypothesized that VZV-induced hypersensitivity depends on ORF47 through 
its phosphorylation of ORF9. Affecting ORF9 protein incorporation into virions, altering cell 
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free virus spread.. Interestingly, we saw two different affects when ORF9 phosphorylation 
mutant viruses were administered to animals. The published ORF9 mutant, ORF9 E85R, resulted 
in no thermal hypersensitivity and only transient mechanical hypersensitivity in animals that did 
not last past 14 days post infection and never returned. A mutant that directly changes the serine 
at position 84 (ORF9 S84A E85R) also generated a burst of mechanical hypersensitivity early, 
which resolved in 2-3 animals, but eventually reappeared in all animals at 29dpi. Thermal 
hypersensitivity showed the same trend for both viruses with ORF9 S84A E85R inoculated 
animals developing an intermediate sensitivity that is not different from either wild type VZV or 
47Kan (as shown in mean area under the curve (Figure 15 D)). While we cannot fully explain 
these results, it is unlikely that the phenotypic change in capsid morphology due to ORF9 
hyperphosphorylation by ORF47 renders the virus unable to infect neurons or is deficient in 
transport back to the soma. Studies with ORF47KO inoculated animals have suggested similar 
numbers of genomes to wild type infected animals in cotton rats and in our model (144 and 
unpublished findings). Altering the serine at position 84 may have unintended consequences on 
the virus and pain responses to it. This mutation may block not only ORF47 phosphorylation but 
also casein kinase II mediated phosphorylation as ORF9 E85R does not completely remove the 
serine at position 84 which can be phosphorylated by casein kinase II, in the absence of ORF47 
193. The double mutant may represent a slower infection that lasts longer, as its growth is slightly 
reduced in vitro, and yet this smoldering infection may result in more pain with a prolonged 
immune response and damage to neurons and their support cells. While this data is intriguing, 
the experiment needs to be repeated. 
We further show that ORF47 is necessary for VZV-induced hypersensitivity in animals 
and is sufficient to generate hypersensitivity when expressed outside of the context of VZV 
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infection. Interestingly, if ORF47 is expressed in replication defective HSV, animals exhibit 
nocifensive behaviors but when the ATP binding domain was mutated, animals did not develop 
hypersensitivity. This suggests that kinase activity of ORF47 can directly contribute to pain 
induction. This may not be surprising given the expression of a viral kinase may result in 
extensive changes in host signaling pathways and phosphorylation events that can affect pain. 
In conclusion we show that ORF47 is necessary and sufficient to induce pain and 
infection with a 47Kan virus does not induce the peripheral neurite retraction seen in wild type 
VZV infected animals. The effects of ORF9 phosphorylation on hypersensitivity is intriguing but 
requires further study. ORF47 would be a good target for novel anti-herpesvirus pain drugs 
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6.0  NOVEL HERPESVIRUS VECTORS EXPRESSING PAIN MODULATORY GENES 
AND THEIR EFFECTS ON HYPERSENSITIVITY IN A RAT MODEL OF VZV-INDUCED 
PAIN 
This chapter is a reprint of a manuscript published in the journal Gene Therapy authored by Jean-
Marc Guedon, William Goins, Mingdi Zhang, Joseph C. Glorioso, and Paul Kinchington. 
All animal work was performed by JGG, MZ, and WFG. WFG and JCG generated the 
HSV vectors expressing human preproenkephalin and its parent (vHG). JGG performed nucleic 
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6.1 INTRODUCTION 
Varicella zoster virus (VZV), a ubiquitous human herpesvirus, causes herpes zoster (“shingles”) 
following its reactivation from a neuronal latent state that was established during the primary 
disease, varicella (“chickenpox”). Herpes zoster is associated with considerable morbidity as a 
result of debilitating acute and chronic pain, with incidence increasing with rising age and/or 
declining immune status. Zoster will eventually occur in approximately 1/5th to 1/3rd of the 
population, usually occurring in those over age 60.27,204 While vaccines for both varicella and 
zoster are available54, the zoster vaccine is only partially effective in preventing the occurrence 
of zoster and pain associated with it.27  
Pain may occur before, during and/or after the skin disease of zoster and even occurs in 
its absence.205 Up to 90% of zoster patients experience acute pain40, which may be alleviated by 
timely antiviral administration to limit viral replication. However, 1/3rd of patients progress to 
develop chronic, more difficult to treat pain states known as Post-Herpetic Neuralgia (PHN) that 
usually fail to respond to antiviral treatments.206 The most common and debilitating pain 
experienced by PHN patients is moderate to severe mechanical allodynia and/or thermal 
hypersensitivity. These may become so severe that they lead to disparate secondary 
consequences such as depression, withdrawal from society and loss in the quality of life.207,208 
Current treatment strategies for PHN include tricyclic antidepressants, topical lidocaine or 
capsaicin patch treatments, opioids and gabapentinoids, but these are often ineffective and 
associated with moderate to severe side effects, poor patient compliance, or abuse.206 PHN 
remains a significant public health concern in urgent need for improved treatment strategies.30   
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Although there is no small animal model of VZV latency, reactivation, zoster-like disease 
and subsequent pain, a rat model of VZV-induced pain has been described.111,117,118,120 Animals 
inoculated at the footpad with VZV-infected cells develop long-term chronic nocifensive 
behaviors similar to those exhibited by PHN patients, including mechanical allodynia (MA), 
thermal hyperalgesia (TH), and anxious-like behaviors.117 VZV-infected animals show a viral 
dose-dependent increase in sensitivity with expression of some VZV proteins in neurons 
colocalizing with peripherin, Neurofilament 200, and Neuropeptide Y in ipsilateral but not 
contralateral ganglia.118 It has been established that pain behaviors developing in the VZV 
inoculated rat model do not respond to acyclovir blockade of viral replication, which mirrors the 
observations that pain in the majority of human PHN patients is not alleviated by antiviral 
therapy.30,116,117,120,206 While the pain indices that develop in the rat differ from human PHN in 
that it follows an acute primary infection rather than a reactivation from latency, the rat model 
has proved highly useful for preclinical assessment of many current and novel drug treatment 
strategies,117,118,120 and many treatments in the rat echo the response of some PHN patients. 
Animals treated with Gabapentin, Morphine, sodium channel blockers (mexiletine and 
lamotrigine), or tricyclic antidepressant (Amitriptyline) showed significant reduction in 
hypersensitivity. However, many drug treatments show only short-term relief, and some of the 
treatment strategies evaluated in the rat require administration routes that are impractical for 
PHN patients.  
Here, we show that nocifensive behaviors developing in VZV footpad-inoculated 
Sprague-Dawley rats are effectively treated and prevented with HSV vector-delivered expression 
of human preproenkephalin (vHPPE).  Preproenkephalin gives rise to natural opioids that 
modulate pain perception, and can be found in interneurons that synapse onto primary and 
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second order neurons in the dorsal horn of the spinal cord.209 Release of vesicle-stored Met- and 
Leu-enkephalin opioids bind and activate ∂-, and to a lesser extent, µ-opioid receptors on both 
primary and second order neurons. This results in the lowering of cyclic AMP production and a 
hyperpolarization of the neuronal membrane, thereby activating inwardly rectifying K+ channels 
with concurrent inhibition of voltage-sensitive Ca++ channels.210 vHPPE is based on replication-
defective herpes simplex virus type 1 (HSV-1), a neurotrophic herpesvirus that establishes 
latency (and expresses) in sensory neurons and is not associated with chronic pain. The effective 
long-term relief of VZV induced pain in the rat promotes the exciting potential for long-acting 
treatment of the PHN that follows Herpes Zoster. 
 
Figure 16: Schematic of HSV vectors used in this study. The top line represents the vHG control vector, 
which has the essential IE gene ICP27 and both copies of essential IE ICP4 gene deleted (bold black lines). The 
virus is also altered to render the ICP22 and ICP47 gene promoters to be expressed as early (or ß-) genes. The 
minimal human cytomegalovirus Immediate Early gene promoter (HCMV IEp) -eGFP expression cassette (black 
box) is inserted into both copies of the ICP4 locus. The lower line represents the vHPPE vector, derived from the 
vHG control vector, which contains the insertion of the cDNA for human preproenkephalin (HPPE, grey box), 
driven by the HCMV IEp, followed by the bovine growth hormone polyadenylation signal (BGHpA), inserted in 
place of eGFP.       
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6.2 RESULTS 
6.2.1 Nocifensive behaviors induced in Sprague-Dawley rats inoculated with VZV  
We first established the model of VZV-induced hypersensitivity in Sprague-Dawley rats, which 
have been used extensively in many inflammatory and neuropathic pain models211. Previous 
reports on VZV induced pain used Wistar rats.111,116-118,120 Nocifensive behaviors were induced 
by VZV pOka, a wild-type varicella isolate of Japanese origin that was the basis for subsequent 
attenuation for use in the current VZV vaccines.46,47 We employed this viral strain since it has 
been used in most genetically manipulatable systems for VZV. Animals were inoculated with 
live cell-associated VZV, because VZV infectivity remains highly cell-associated and cell-free 
virus cannot be obtained at the titers required to induce pain. All animals receiving VZV in 
multiple studies developed markedly different behavioral responses to mechanical and thermal 
stimulation compared to animals receiving uninfected cell equivalents (Figure 17a,b) or sham-
inoculated animals (data not shown). No difference was observed between control cell-
inoculated animals and sham-inoculated animals. Chronic hypersensitivity to mechanical stimuli 
developed only in the VZV-inoculated paw, resulting in a biased ipsilateral/contralateral ratio 
lasting several weeks. The contralateral paw of animals receiving VZV did not respond to most 
von Frey filament stimulations, as seen in the ipsilateral or contralateral paws of animals 
receiving uninfected cells. Significant hypersensitivity to thermal stimuli (Figure 17b) also only 
developed in VZV-injected footpads as compared to the un-inoculated contralateral paw or 
uninfected cell inoculated paws. VZV-induced nocifensive behaviors persisted in this study for 
approximately 5 weeks post infection (wpi), whereupon hypersensitivity responses reduced, and 
by 6-8 wpi, were similar to untreated animals. Timing of spontaneous recovery showed 
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consistency between groups of animals within the same experiment, although rats in other 
studies showed variation in the time at which spontaneous resolution occurred. We also 
evaluated MA and TH responses in rats receiving VZV preparations that were UV-inactivated 
just prior to inoculation. These showed no significant mechanical or thermal hypersensitivity 
(Figure 17). This indicates that the VZV-infected cell inoculum used in these studies did not 
contain pre-existing factors inducing the hypersensitivity, and that live virus with de novo 
transcription and gene expression are required for the induction of pain.   
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 Figure 17: Mechanical and thermal hypersensitivity induced by VZV in Sprague-Dawley rat requires 
de novo transcription. Animals were pretested 2 days prior to infection for baseline MA and TH responses, and 
then inoculated (n=4 per group) at day 0 with 2x105 PFU of pOka or uninfected cell equivalents. Animals were 
evaluated for (a) mechanical allodynia (MA) scores using von Frey filaments and for (b) thermal hyperalgesia using 
a Hargreaves apparatus, as detailed in the methods with the graphs depicting the ratio of ipsilateral to contralateral 
responses. Mean +SEM is plotted. This study is representative of three similar studies. Statistics used One-Way 
ANOVA between groups and Dunnett’s multiple comparison test comparing groups to MeWo. Mean area under the 
curve is plotted for each animal; line represents the mean and bars are SEM (c). Mean area under the curve with 
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One-Way ANOVA between groups and Tukey’s multiple comparison test, with *=P<0.05, ***=P<0.001 indicating 
significance. 
6.2.2 HSV vector PPE expression modulates VZV-induced nocifensive behaviors  
While novel drug treatments have been evaluated in the rat PHN model, most provide only a 
short-lived relief of pain and often require administration routes that would be impractical for the 
treatment of human PHN. Given human PHN can be prolonged, a long-term treatment strategy 
would be desirable. Therefore, we evaluated treatment using a replication-defective HSV-1 
vector expressing human PPE (Figure 16).132 Rats inoculated with VZV and showing significant 
mechanical and thermal hypersensitivity by 19 dpi (Figure 18) were then inoculated at the same 
footpad with PBS or 108 infectious units of HSV vector (vHPPE or vHG control). Animals 
receiving PBS or vHG continued to show significantly biased MA and TH 
ipsilateral/contralateral responses after vector administration (Figure 18a,b). Remarkably, VZV-
induced MA and TH nocifensive responses showed prolonged relief following a single 
inoculation of 108 vHPPE (Figure 18b,d). Neither HSV vector induced changes in behavioral 
responses of uninfected cell inoculated rats (Figure 18c). These results strongly suggest that 
HSV-1 vector-mediated expression of human PPE could effectively alleviate VZV-induced 
nocifensive responses in the rat model for extended periods.    
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 Figure 18: Administration of vHPPE provides prolonged relief of VZV-induced hypersensitivity. 
Animals were injected on day 0 with 2x105 PFU of pOka or equivalent number of uninfected MeWo cells (n=5 per 
group) and assessed for MA and TH at times shown. At 19 dpi, animals were injected with 108 PFU of vHPPE, vHG 
or equivalent volume of PBS and subsequently evaluated for (a, b) MA using von Frey filaments and (c, d) TH using 
a Hargreaves apparatus. All results are presented as a ratio of the score of the ipsilateral to contralateral sides. Mean 
+SEM is plotted. Arrowheads indicate when HSV vectors were administered. The study shown is representative of 
two studies with similar results. Statistics used One-Way ANOVA between groups and Dunnett’s multiple 
comparison test comparing groups to pOka + PBS. Mean area under the curve is plotted for each animal; line 
represents the mean and bars are SEM (e). Mean area under the curve with One-Way ANOVA between groups and 
Tukey’s multiple comparison test, with *=P<0.05, ***=P<0.001 indicating significance. 
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To evaluate whether alleviation of nocifensive behaviors by HSV delivered PPE was 
dose dependent, incremental lower doses of the HSV vectors were examined. All rats injected 
with VZV-infected cells developed nocifensive behaviors. On day 19, VZV-infected and control 
animals were inoculated with either PBS, 104 or 106 PFU per footpad of vHPPE or vHG control, 
respectively. Rats receiving PBS treatment or HSV vHG at 104 or 106 PFU continued to show a 
biased MA footpad response to the VZV-inoculated paw (Figure 19a,b). In contrast, animals 
with a VZV-induced hypersensitivity that received vHPPE at 104 or 106 PFU developed obvious 
relief from MA within 14 days of administration. However, the MA response in rats receiving 
the lower dose (104 PFU/footpad) showed only short-term alleviation, and biased MA responses 
returned in the VZV-infected paw at 42 dpi of VZV. This result indicated that relief of the MA 
responses by vHPPE was dose-dependent. However, the short-term relief by vHPPE could be re-
initiated by re-administration of 108 PFU of vHPPE at 53 dpi (Figure 19a). Such animals showed 
an immediate relief from VZV-induced nocifensive behaviors that then persisted for the length 
of the study. Thermal responses were concurrently evaluated and while they showed a similar 
trend, statistical difference could not be established between the groups (data not shown). We 
conclude that vHPPE can modulate VZV-induced nocifensive responses in a dose-dependent 
manner that affects duration of analgesia and does not preclude potential for re-administration 
and extension of relief.     
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 Figure 19: VZV-induced nocifensive behaviors respond to reduced vHPPE dosing and vector re-
administration. Animals were evaluated for MA at day 0 and then injected with 2x105 PFU of pOka or equivalent 
number of uninfected MeWo cells (n=5 per group), followed by MA evaluation at day 7 and 16. At 19 dpi, animals 
were injected with either (a) 104 or (b) 106 PFU of vHPPE, vHG or PBS. Animals were evaluated for sensitivity by 
MA calculated using von Frey filaments and the ipsilateral to contralateral ratios calculated. All animal experiments 
were repeated with similar results. Animals that were originally dosed with (a) 104 PFU of vHPPE or vHG were 
given a later dose of 108 PFU of vHPPE at 53 dpi. Mean +SEM plotted. Arrowheads indicate when HSV vectors 
were administered. Statistics used included one-way ANOVA between groups and Dunnett’s multiple comparison 
test comparing groups to pOka + PBS. Mean area under the curve is plotted for each animal; line represents the 
mean and bars are SEM (c), was analyzed by One-Way ANOVA between groups and Tukey’s multiple comparison 
test, with *=P<0.05, ***=P<0.001 indicating significance. 
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 6.2.3 Prophylactic vHPPE administration prevented VZV induced hypersensitivity 
Zoster is often associated with prodromal signs that predict the development of 
disease,212,213 so it is feasible that prophylactic treatment could prevent VZV-induced pain. To 
evaluate this, animals were first inoculated with PBS or 108 PFU of control vHG or vHPPE, 
followed by VZV inoculation at the same site. Nocifensive behaviors were not induced by the 
HSV vectors alone (data not shown), mirroring previously reported absence of pain from 
replication-competent HSV 214-221 or replication-defective HSV 132,222-229, even when expressing 
reporter genes or other proteins. However, VZV-induced MA nocifensive behaviors only 
developed in animals pre-inoculated with PBS or vHG vector, and did not develop in vHPPE 
treated animals (Figure 20). As such, we conclude that prophylactic administration of vector 
vHPPE can block the development of VZV-induced pain. 
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 Figure 20: Prophylactic administration of vHPPE blocks development of VZV-induced Mechanical 
hypersensitivity.  Animals were injected 7 days before VZV infection with either 108 PFU of vHPPE, vHG or PBS. 
On day 0, animals were inoculated with 2x105 PFU of VZV pOka or uninfected MeWo cell equivalents (n=5 per 
group). MA scores were determined at the indicated times using von Frey filaments and are presented as a ratio of 
ipsilateral to contralateral paw responses. All animal experiments were repeated with similar results. Mean +SEM is 
plotted. Statistics used One-Way ANOVA between groups and Dunnett’s multiple comparison test comparing 
groups to pOka + PBS and Mean area under the curve is plotted for each animal; line represents the mean and bars 
are SEM (b) was analyzed for significance using One-Way ANOVA between groups and Tukey’s multiple 
comparison test, with *=P<0.05, ***=P<0.001 indicating significance.  
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6.2.4 VZV-induced hypersensitivity and its relief by PPE do not act at the periphery 
VZV-induced hypersensitivity and its relief by peripheral administration of vHPPE were 
suspected to act at the ganglia, but it is possible that vHPPE-expressed enkephalin acts on 
sensory nociceptor termini at the periphery. Direct quantification of enkephalin expression was 
not sufficiently sensitive to reveal differences between treated and untreated controls, as seen 
previously.132 Global quantification of innervating ganglionic transcripts of human PPE mRNA 
revealed a 3-5 fold 2^(-∆∆Ct) increase in levels over that detected in control animals (Figure 21).    
 
Figure 21:  Ganglionic expression of human PPE in animals injected with vHPPE. Animals were 
inoculated with 108 PFU of vHPPE or vHG and sacrificed at 1 and 2 weeks post inoculation (n= 6 per group). The 
L4-6 DRGs were removed and the extracted RNA was converted to cDNA. Transcripts for human PPE were 
quantified by Taqman RT-PCR and are presented using the 2-∆∆Ct compared to rat GAPDH as a surrogate for 
normalized gene expression against control animals. Mean ±SEM is plotted.  
 
To further probe for effects at the periphery, we analyzed whether peripheral 
administration of DAMGO or naloxone affected VZV-induced pain or its relief by vHPPE 
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administration. Animals showing VZV-induced nocifensive MA behaviors at 3 wpi were 
subcutaneously injected at the footpad with 1 or 10µg of DAMGO, a synthetic µ-opioid receptor 
agonist with high specificity for the µ-opioid receptor. We reasoned that the peripheral 
administration of DAMGO would alter VZV-induced pain responses if a mechanism of vHPPE 
relief acted at the periphery (Figure 22). However, VZV-induced biased MA responses showed 
no detectable relief immediately following DAMGO administration into the footpad. Higher 
dosing with 10µg DAMGO did not lead to any relief of nocifensive behaviors over a period of 1 
h. We then assessed if peripheral administration of naloxone to the footpad would negate relief 
of VZV-induced MA responses by 108 vHPPE. Peripherally delivered naloxone, a competitive 
antagonist of the opioid receptors, would be expected to block enkephalin interaction with any 
peripherally located opioid receptors, but not with DRG axons terminating within the dorsal horn 
of the spinal cord. VZV-infected animals showing nocifensive behaviors that were then relieved 
by 108 HSV vHPPE showed no biased MA responses, while control animals continued to show a 
strong ipsilateral to contralateral bias (Figure 23). Animals receiving either 5 or 50µg of 
naloxone in the same paw showed no change in MA responses, either short term (up to 60 min) 
or after 24 h post administration (data not shown). Furthermore, peripheral naloxone 
administration did not affect vHPPE relief of VZV-induced nocifensive behaviors, suggesting 
that HSV vector-mediated expression of enkephalin within the DRG acts centrally within the 
spinal cord. The latter has been strongly implied from prior studies using similar pain relieving 
vectors, in which blockade of the effects of enkephalin were obtained following intrathecal 
administration of antagonists 164,223,230-232. We conclude from this data that it is unlikely that 
VZV-induced pain and its relief induced by vHPPE vector were due to effects mediated at the 
periphery. 
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 Figure 22: Effect of peripheral delivery of DAMGO on VZV-induced MA hypersensitivity.  Animals 
inoculated with 2x105 PFU of pOka at the footpad were housed to allow the development of MA hypersensitivity. 
Animals were evaluated to determine baseline responses and then injected with 1 or 10µg/20µL DAMGO or 
equivalent volume of PBS at 9 dpi (n=4). Animals were subsequently tested for mechanical sensitivity by von Frey 
filaments and presented as an ipsilateral to contralateral ratio. Times of MA assessment were 10 min before injection 
for baseline determination and 5, 20 and 60 min post injection. Mean ±SEM is plotted.  
 
Figure 23: Effect of peripheral delivery of naloxone on VZV-induced MA hypersensitivity treated 
with vHPPE or vHG vector. Animals were inoculated with 2x105 PFU of pOka, and then received at 9 dpi either 
108 PFU of vHPPE, vHG or PBS. Animals received a third footpad injection at 23 dpi with 5 or 50µg/20µL 
naloxone or the equivalent volume of PBS (n=4). Animals were tested for mechanical hypersensitivity by von Frey 
filaments, 10 min before injection and 5, 20 and 60 min post injection. The ratio of ipsilateral to contralateral paw 
responses is shown. Mean ±SEM is plotted. 
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6.3 DISCUSSION 
The goal of this study was to further develop a rat model of VZV-induced pain to evaluate the 
therapeutic and prophylactic administration of human enkephalin using an HSV vector 
ganglionic delivery system. The efficacy of this strategy strongly promotes the potential for use 
of enkephalin gene delivery as a long-acting treatment for the pain and PHN associated with 
zoster. The model appears robust and reproducible, particularly with respect to induced 
mechanical hypersensitivity, but it is not yet clear exactly how VZV induces nocifensive 
behaviors in rats. The length of hypersensitivity in rats was found to vary somewhat between 
different experiments. We postulate that this could be the consequence of the out-bred strain and 
subtle differences in the genetics of these animals. It is also possible that subtle variations in the 
experimental procedures and even subtle changes in housing conditions could contribute to this 
variation, although every step was taken to minimize these experimental differences. We note 
that the duration of chronic nocifensive behaviors were also variable in previously reported 
studies using the Wistar rat model.116-118 However, the variation reflects the duration of extended 
pain in PHN patients, which may be short or last for years. Differences may also be the 
consequence of virus strain used. Each lab has evaluated different strains in the rat model that 
differ from the virus we employed here, parent Oka (pOka). However, we point out that the 
pOka strain is the standard virus most employed in the field of VZV genetics and should be 
useful for future genetic studies to evaluate pain-inducing VZV genes in the rat model. Most 
rodents are not permissive for VZV replication although some early phases of infection may 
occur. Two separate studies have reported that the development of VZV-induced pain behaviors 
in rats is not prevented by the viral DNA replication inhibitor, acyclovir.116,117 However, given 
that some viral gene products can be detected in neurons of the innervating ganglia, but not in 
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contralateral ganglia (including VZV immediate early proteins IE62 and IE6330,117,118), it seems 
likely that an abortive type of infection with some viral gene expression is required for pain 
development. Our data showing that rats receiving UV-inactivated VZV failed to develop 
hypersensitivity behaviors is consistent with this hypothesis, since it indicates infectivity and/or 
de novo VZV gene transcription are required. We suspect that transcription of VZV genes within 
virus-infected neurons may themselves lead to the chronic pain state either through induction of 
inflammatory mechanisms or through expression of proteins, such as transcriptional regulators, 
that may alter host cell expression patterns.118,233,234 Studies are ongoing to determine if viral 
transactivators, IE62 and IE63, are required for the induction of the chronic pain state.  
We show that VZV-induced pain behavioral indicators can be effectively reversed and 
even prevented with sustained effect by HSV vector-mediated delivery of preproenkephalin. We 
exploited replication-defective HSV-1 vectors, which are engineered to enter a latent-like state in 
sensory neurons.  In contrast to VZV, human HSV recurrent infections are not associated with 
more than slight acute pain. Indeed, Wistar rats inoculated with high titers of replicating HSV-1 
show only momentary behavioral pain responses.116 Consistent with this we found no pain 
indicators developing in Sprague-Dawley rats inoculated with either vHG control vector or 
vHPPE vector (data not shown) as has been previously described in replication-competent HSV 
214-221 or replication-defective HSV 132,222-229 vectors expressing genes other than enkephalin in 
various pain models. This supports the fact that while HSV and VZV are genetically related, they 
have very different consequences on pain induction. Additionally, this is consistent with a 
variety of HSV vectors that do not induce pain in preclinical animal models and human clinical 
trials.214,235 This supports the safety for the potential use of such vectors in humans. Our study 
extends the application of this vector–gene delivery combination to a model of a common and 
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significant clinical problem, PHN. HSV-1 vectors expressing human preproenkephalin have been 
used in various other pain animal models including: pain associated with pancreatitis216,227, 
formalin-injection223, spinal nerve ligation226, complete Freund’s adjuvant (CFA)-induced 
arthritis215,219,221, chronic constriction injury (CCI)220,229, bone cancer pain222, pertussis toxin 
induced pain217, and in a bladder nociception model.132,224,225 In these studies, HSV vector-
mediated enkephalin produced abrogation of nocifensive behaviors to varying extents. The long-
term effects of such vectors and their peripheral administration are particularly attractive for 
application to PHN, which may last weeks to years. Evaluation of morphine, amitriptyline, 
gabapentin, ibuprofen and the Win55212-2 2 compound in the rat PHN model117 all provide only 
temporary relief lasting 4-6 days or less, and some human treatments such as Morphine are 
associated with tolerance and abuse issues. Oral administration of gabapentin, or the sodium 
channel blockers mexiletine and lamotrigine were also found to last for hours or less in the rat 
model.118 Short-term effects on VZV pain in the rats by agents such as the astrocyte toxin LAA, 
as well as iNOS inhibitors (L-NIL), NO scavengers (PTIO), IL1 receptor antagonist, the cytokine 
inhibitor pentoxifylline, NMDA receptor antagonists (AP5 and (R)-CPP), and the non-
competitive NMDA receptor antagonist MK801 have also been reported, but these require 
intraperitoneal or intrathecal administration, routes not particularly suited to human 
treatment.117,118,120 The single peripheral administration of vHPPE abrogated VZV-induced 
nocifensive behaviors completely at high doses (Figures 18b,d). We argue this is the first 
strategy to show a prolonged effect on VZV-induced pain behaviors with single dosing and 
relatively simple administration. The potential for vHPPE re-administration (Figure 19) was also 
demonstrated. A similar replication-defective HPPE expressing HSV vector has been evaluated 
in a Phase-I trial for patients with intense chronic cancer related pain, and reduced pain scores.235 
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We believe our data establishes a basis for evaluating the efficacy of this vector in human PHN 
trials. 
The presumed mechanism(s) of action in the enkephalin treatment strategy is that 
following HSV infection of sensory nerves, ganglionic expression of enkephalin probably results 
in Leu- and Met-enkephalin incorporation into secretory vesicles and release at synapses of 
sensory nerve axons terminating within the dorsal horn of spinal cord, where binding to opioid 
receptors prevents synaptic transmission of pain signals. Our studies with the peripheral 
administration of enkephalin agonists and antagonists suggest that enkephalin is acting centrally. 
Previous reports222,223 indicate that intrathecal administration of naltrexone, an opioid receptor 
antagonist, reversed HSV-ENK vector-mediated relief, suggesting a central acting role for 
enkephalin in those models. In our VZV PHN model peripheral injection of DAMGO or 
naloxone had no influence on hypersensitivity or effect on vHPPE-mediated relief, respectively. 
All time points had similar effects, suggesting local delivery of opioid receptor agonist or 
antagonist does not alleviate hypersensitivity or block analgesia. This further supports the 
hypothesis that HSV vector-mediated enkephalin acts centrally.  
Taken together, we have established that VZV induces a robust mechanical and 
quantifiable thermal hypersensitivity in Sprague-Dawley rats, which is dependent upon de novo 
VZV gene expression. These pain behaviors can be effectively relieved for prolonged periods by 
peripheral administration of an HSV vector expressing human PPE, and can be prevented from 
developing by prophylactic vector administration. These studies suggest further development of 
these or similar vectors as prolonged treatment strategies for pain associated with Herpes Zoster.   
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7.0  DISCUSSION AND FUTURE DIRECTIONS 
7.1.1 Viral expression is necessary for hypersensitivity in the rat 
Here we demonstrate that VZV gene expression/infectivity is necessary for the establishment of 
hypersensitivity in rats (Figure 17). Others have shown that treatment with the viral DNA 
synthesis inhibitor, acyclovir or its derivatives, does not affect hypersensitivity in animals 117,120. 
Taken together these data suggest that full viral replication is not needed to induce 
hypersensitivity in animals.  
We have observed very little viral replication in animals particularly in innervating 
ganglia. Therefore, we sought to identify the block in viral replication utilizing rat primary tissue 
as a surrogate for VZV infection. Primary cultures infected with VZV reporter viruses showed 
luciferase expression. However, both kinetic classes are not expressed to the levels as seen in 
permissive cells, with late gene expression at or below input cell-associated virus luciferase 
expression (Figure 4). Viral RNA obtained from infected ganglia confirmed the lack of late gene 
expression, but immediate early and early genes were detected (Figure 5). These data suggest 
there is a block in viral replication that occurs after immediate early gene and before late gene 
expression. Our data suggest that in rats, the block in VZV replication appears before DNA 
replication, as DNA copies do not increase in DRGs and late genes are not expressed. This could 
be the result of a lack of compatible host gene products or a lack of VZV gene products needed 
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for DNA replication. The latter could be established by comparing the expression of VZV genes 
involved in DNA replication between permissive and nonpermissive cells. These genes include 
the large and small subunits of the viral DNA polymerase (ORF28 and 6), DNA binding protein 
(ORF29, which we have shown to be expressed in vivo (Figure 5)), origin binding protein ORF5, 
and the primase-helicase complex (ORFs 6, 52 and 55). A more intensive and expansive 
detailing of host and viral gene expression in permissive and nonpermissive cells would 
elucidate if there are any obvious changes between the two, though this would be resource and 
time intensive. 
7.1.2 Host Changes upon VZV infection 
The host changes that are incurred upon VZV infection have to this point been largely 
unexplored. One group reported changes in microglial activation in the spinal cord and another 
group looked at immunoreactivity of proteins indicative of neuropathic pain, but we are the first 
to report analysis of host transcriptional changes upon VZV infection in the rat (Figure 7) 118,120. 
We have confirmed some of the data by qPCR (Figure 8). The changes we have thus far 
described include TRADD, Ntrk2, TRPV1, and CALCA. It will be important to determine if 
these changes extend to protein expression. Whole DRG were used for the above analysis, but 
the vast majority of cells in the DRG are likely uninfected. Dissociating DRG and obtaining only 
the VZV infected cells would be helpful to determine the full extent of viral infection on the 
various cell types present in DRG. Of course excising and dissociating DRG will likely induce 
changes to host and viral gene expression that may confound our findings.  
A major question remains: what neurons do VZV infect and how do they contribute to 
PHN? In order to answer this question we would need to mark infected neurons. We could 
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accomplish this in two ways: using a Cre responsive animal or a betagalactosidase-expressing 
virus. Unfortunately, Cre responsive rats are not available; however, a betagalactosidase-
expressing virus would circumvent this limitation. Removal of innervating ganglia and assessing 
infection with X-gal staining will allow us to analyze, histologically, which size neurons VZV 
infects. In addition, more careful analysis of neurons infected with VZV could be accomplished 
using fluorescent VZV viruses. Analyzing viral infection of neurons using this method has 
proved difficult due to low fluorescent signal. Tagging a more abundantly expressed gene, such 
as ORF29 (DNA binding protein), may provide adequate signal to be detected. Once marked, we 
could analyze VZV infected neurons for expression of activated transcription factor 3, galanin, 
neuropeptide Y, and activated caspases. Furthermore, Terminal deoxynucleotidyl 
transferase dUTP nick end labeling (TUNEL) assay could be used to determine if VZV infected 
neurons are dying. 
We have also observed a reduction in peripheral neurite innervation due to VZV 
infection. This retraction does not occur in control cell or UV-inactivated VZV inoculated 
animals. This aspect of the rat model mimics what is seen in zoster and PHN patients, with PHN 
patients having more severe denervation than zoster patients 141,160. There are still two major 
questions that remain: which neuron subtype is retracting and does reinnervation correlate to 
hypersensitivity returning to baseline? To determine which type of neuron is retracting we could 
stain footpad sections for NF200, IB4, CGRP, and TRPV1. I hypothesize that reinnervation and 
resolution of hypersensitivity will not correlate, as human skin from PHN patients does not re-
innervate by 6 months after the zoster rash has resolved and pain and hypersensitivity have 
subsided 236. 
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We have yet to determine if the hypersensitivity in the rat model is a result of ganglionic 
infection or if the hypersensitivity is the result of peripheral effects of viral infection and the 
associated clearance. Our preliminary data suggest that there is not a large infiltrate of nucleated 
cells (H&E staining) into glabrous skin from animals inoculated with VZV at 10dpi. We have 
observed a T cell infiltrate into VZV infected ganglia, with CD45/CD4+ cells significantly 
increased at three weeks post infection (Figure 24). However, hypersensitivity begins as early as 
one week post infection, which is shorter than any unprimed adaptive response. The role of 
innate immune responses in the DRG and skin would likely address whether or not there is an 
immune component to VZV-induced pain. Before further analysis, the effects of immune 
depletion should be tested for its effects on VZV-induced hypersensitivity in rats. This could be 
accomplished by making animals immunodeficient via intraperitoneal injection of high dose 
steroids. If animals do see relief or blockade of pain behaviors, then analysis of peripheral and 
ganglionic infiltrates should be pursued, with an emphasis on innate immune cell infiltrate (e.g. 
CD11b+/Ly-71 macrophages, CD335+ natural killer, and CD11c/CD123+dendritic cells). 
Interestingly, pain generated by gp120 of HIV appears to be at least partially mediated by 
increased cytokine and chemokine expression 195,200-203. Analysis of cytokine and chemokine 
expression profiles of DRG, dorsal horn of the spinal cord, and peripheral skin would determine 
their correlation to VZV-induced pain. 
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 Figure 24: VZV infected ganglia have infiltrating CD45+, CD4 or CD8+ T cells. Animals were 
inoculated with either control cells or VZV (pOka) a 0dpi and DRG were harvested at 1, 2, 3, 4, and 6 weeks post 
infection. Ganglia were dissociated with collagenase and stained for CD45, CD4 and CD8. Samples were run on a 
fluorescence assisted cell sorting machine, gated on live lymphocytes, based on forward and side scatter and then 
subgated as CD45+ (A) and then quantified as either CD45/CD4+ or CD45/CD8+ (B). Mean±SEM plotted. Two 
tailed T test used to determine significance. *=P<0.05. 
Lastly, we have only investigated VZV-induced pain in young, male rats. An important 
consideration would be the effects of VZV in aged and/or female animals. Zoster 
disproportionately affects the aged with the risk of PHN greatly increased in people over the age 
of 80 27. Aged animals may more accurately reflect PHN. We utilize male animals to avoid the 
estrous cycle confounding our findings; however, it would be interesting to test hypersensitivity 
in female Sprague-Dawley rats on a matched estrous cycle to determine if sex plays a role in 
VZV-induced hypersensitivity.  
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7.1.3 Viral genes necessary for VZV-induced pain 
We have shown that ORF47, a viral serine/threonine protein kinase, plays a role in VZV-induced 
pain. Animals inoculated with two different ORF47 knock out mutants do not exhibit 
hypersensitivity to mechanical or thermal stimuli, but animals infected with a rescued virus do 
(Figure 9). Interestingly, animals inoculated with an HSV vector expressing VZV ORF47 have 
quantifiable mechanical and thermal hypersensitivity (Figure 11). We further defined the 
necessity of ORF47 kinase activity for the induction of hypersensitivity in rats, as animals 
inoculated with kinase active site mutants do not exhibit hypersensitivity (Figure 10, 11). Other 
mutations that do not affect kinase activity also do not induce hypersensitivity (Figure 10).  
ORF9 is a structural protein involved in virion release from the cell surface.  This 
function is partially mediated by phosphorylation of ORF9 by ORF47. Interestingly, animals 
infected with phosphorylation mutants of ORF9, which are phenotypically similar to ORF47 
knock out viruses, have two different effects on hypersensitivity. A conservative mutation that 
does not alter the serine at position 84 results in no thermal and only transient mechanical 
hypersensitivity that returns to baseline by 14dpi. A more extensive mutant that alters the serine 
at position 84 induces hypersensitivity to mechanical and thermal stimuli. Taken together our 
data suggests ORF47 is necessary and sufficient for the induction of hypersensitivity in rats. This 
may be a result of ORF47 mediated phosphorylation of ORF9, but this hypothesis requires 
further investigation.  
Our data on the role of ORF9 hyperphosphorylation in VZV-induced hypersensitivity is 
intriguing. In order to confirm that phosphorylation of the serine at position 84 in ORF9 is 
necessary for hypersensitivity in rats, we would also need to investigate animals inoculated with 
a phosphomimetic ORF9 in an ORF47 deficient virus. We could accomplish this by altering the 
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serine at position 84 to an aspartic acid (ORF9 S84D ORF47Kan, or multiple serines if 
hyperphosphorylation is needed), which will act as a constitutively phosphorylated ORF9 in the 
backbone of a virus that does not express ORF47. The in vitro characterization of the virus 
including electron microscopic analysis of virions and viral growth kinetics will need to be 
reexamined. However, if phosphorylation of ORF9 is involved in VZV-induced pain, animals 
infected with ORF9 S84D ORF47Kan would still exhibit hypersensitivity. 
We also need to address whether ORF47 affects viral infection of neurons and for 
transport back to the soma. This is unlikely as VZV genomes are detected in ganglia of 47Kan 
infected rats, and 47Stop virus inoculation did not change the viral genome burden in cotton rats 
at latency 144. We also need to address if ORF47 deficient viruses affect the rate of transport to 
the soma of neurons. I have made a fluorescent ORF47 knockout with mCherry tagged to 
ORF23. This virus would be ideal for testing in human embryonic stem cell derived neurons. If 
47Kan VZV travels at a reduced rate or does not reach the soma, it may be an excellent 
candidate to replace current vaccines, especially for the prevention of varicella, since this mutant 
would affect the establishment of latency. If the virus does travel back to ganglia, then 
characterization of its viral gene expression by RNAseq or nanostring would help determine if it 
has any gross defects affecting its ability to generate pain. An exhaustive study of host and viral 
gene targets for ORF47 would better our understanding of the biology of the virus and could also 
lead to new targets for pain therapeutics. 
Animals inoculated with ORF47 knock out viruses still exhibit limited sensitivity to 
mechanical and thermal stimuli. This suggests that ORF47 may not be the only viral gene 
affecting hypersensitivity. Elucidating other viral genes that affect pain remains an area of active 
investigation in the laboratory. One candidate could be IE62 as animals inoculated with an HSV 
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vector expressing IE62 (the homolog of ICP4) exhibit nocifensive behaviors (Figure 25). 
Animals inoculated with a control vector or a vector expressing another immediate early gene, 
IE63, do not develop hypersensitivity. This suggests that IE62 is sufficient to generate 
hypersensitivity. The mechanism for this IE62 mediated hypersensitivity is unknown, but may be 
related to an epitope in IE62 that produces an immune response to host BDNF 146. We have made 
a virus that has the cross reactive epitope removed and would be interested in testing this 
hypothesis in vivo. It is also possible that expression of IE62, a transcription activator, affects a 
multitude of cellular processes and influences chronic hypersensitivity during VZV infection.  
 
Figure 25: VZV genes expressed by HSV vectors generate mechanical hypersensitivity. HSV vectors 
expressing VZV ORFs 47, 62, 63, or 66 were inoculated into animals at day 1 and measured for mechanical 
hypersensitivity. Data plotted as ratio of ipsilateral response / contralateral, Mean+SEM. 
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7.1.4 New treatments 
This model serves as an excellent platform to test novel therapeutics. We 
have shown here that treatment of VZV-induced pain in animals using herpesvirus vectors that 
express pain modulatory genes is not only possible but also effective. Recently, we have 
expanded our efforts to include HSV vectors that express glycine or ivermectin sensitive chloride 
channels. These channels can be selectively activated through the application of glycine or 
ivermectin, respectively, and animals inoculated with the vector and administered the appropriate 
agonist reduced hypersensitivity in a dose dependent manner (Figure 26). However, animals 
treated with HSV-GlyR and administered various doses of ivermectin, or animals transduced 
with HSV-GlyRM and administered various doses of glycine remained hypersensitive. The use 
of HSV vectors to treat chronic pain conditions like PHN remain tantalizing, but require further 
study. 
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Figure 26: Treatment of VZV-induced pain with HSV vector expressed glycine or ivermectin 
sensitive chloride channels. Animals were inoculated (n=5 per group) at day 0 with 2x105 PFU of VZV and 
evaluated for mechanical sensitivity using von Frey filaments (displayed as paw withdrawal threshold in the 
ipsilateral paw), once VZV-induced hypersensitivity was repeatedly observed (20dpi), animals were inoculated with 
108PFU of control vector (HSV-GFP), a vector expressing a glycine sensitive chloride channel (HSV GlyR), or a 
vector expressing a mutant glycine derived chloride channel that responds to ivermectin. After 1-week post 
transduction, animals were tested for hypersensitivity 15 minutes after administration of vehicle (PBS), glycine, or 
ivermectin at the indicated concentrations. The Mean +SEM is plotted. 
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Another avenue that remains intriguing is the role of TrkB signaling in VZV-induced 
pain. It has been previously reported that a cross-reactive epitope in IE62 causes an antibody 
response in mice that also reacts with human/mouse BDNF. The authors show that these cross-
reactive antibodies, when administered to cells, result in increased cell body area, dendrites and 
number of branches in neurons. They also show that a proportion of PHN patients have these 
cross-reactive antibodies, presumably leading to their chronic pain state. BDNF binds to and 
activates its receptor TrkB (Ntrk2), which we observe to be increased in our VZV infected 
animals (Figure 7 and 8). Taken together, these data suggest a role for BDNF/TrkB signaling in 
PHN and merits further study. Perhaps blocking this pathway can help alleviate the initiation of 
pain and serve as a new therapeutic for PHN.  
This model serves as the only platform for the testing of treatments for PHN. Therefore, 
combination therapies that include low dose Gabapentin with a BDNF inhibitor would be 
interesting to pursue in this model.  
There are drawbacks to this model as discussed in chapter one, with a major concern 
being the model’s sensitivity. Many treatments seem to achieve the same reduction in sensitivity 
while targeting very different processes. It remains unclear the exact mechanism for chronic pain 
induced by VZV, and if there is only one etiology or a multiple of different processes that result 
in the same end as has been suggested. Although the model is not perfect, rats are the only small 
animals known to exhibit nocifensive behaviors.  
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